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Abstract
Like many natural resource-based processing industries, the seafood processing sector gives 
rise to a significant volume o f organic waste, Environmental issues, economic concerns and 
legal restrictions regarding the disposal o f  processing wastes have led to increased research in 
the discovery o f alternative value-added products, such as bioactive peptides from these 
waste streams. Bioactive peptides have various physiological functionalities in the human 
body following consumption and these include antihypertensive, anti-amnesiac, mineral- 
binding, immunodulatory, antioxidative and antithrombotic activities, The main focus o f this 
thesis was to examine whether mackerel and whelk fisheries processing by-products and 
mackerel meat tissues are suitable sources for the isolation o f  angiotensin-I converting 
enzyme (ACE-I) and prolyl endopeptidase (PEP) inhibitory peptides. This thesis outlines the 
steps involved in the preparation o f  fish waste hydrolysates using enzymes, development o f 
bioassays to monitor ACE-I and PEP inhibitory activities, application o f capillary 
electrophoresis for ACE-I inhibitory activity and the concentration o f peptidic fractions using 
membrane filtration techniques.
Ecostone®A200, Corolase® N, Corolase® PP, Corolase® LAP, Pepsin and Thermolysin were 
used as suitable hydrolytic enzymes for the production o f ACE-I and PEP inhibitory peptides, 
Whelk waste consisting o f shell discards were hydrolysed using the Ecostone®A200 
polysaccharide hydrolytic enzyme. Mackerel waste which consisted o f white meat and 
brown meat tissues and head, tail and skin discard portions were hydrolysed using the 
Corolase® N, Corolase® PP, Corolase® LAP, Pepsin and Thermolysin proteolytic enzymes. 
ACE-I and PEP bioassays identified potential ACE-I inhibitory activity o f mackerel samples 
with inhibition values o f up to 39% (± 7.02) while PEP inhibitory activity occurred for all 
hydrolysates and ranged from 35 (± 1.35) to 78% (± 1.88) inhibition. ACE-I inhibitory 
assays results were confirmed using a purified ACE-I enzyme source and a developed 
capillary electrophoresis ACE-I inhibitory assay protocol. ACE-I inhibitory activities for the 
same hydrolysates used in the ACE-I bioassay increased to 100% inhibition with positive 
ACE inhibitory activity ranging from 71 -  100% depending on the mackerel tissue source 
and hydrolytic enzyme employed, Two o f the ACE-I inhibitory samples from different 
mackerel tissues were further concentrated using membrane filtration techniques through 
molecular weight cutoff (MWCO) filters (10 kDa and 3 kDa), The purpose o f this was to 
ascertain if there were potentially a number o f various sized peptide inhibitors present and to
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assess if the hydrolytic conditions resulted in partial hydrolysis o f  the inhibitory peptides 
present in the samples. Results indicated that the experimental strategy employed and the 
utilisation o f  marine waste may serve as an approach to identifying novel bioactive peptides.
ACE-I: Angiotensin-I-converting enzyme
BGE: Background electrolyte
BIM: Bord Iascaigh Mhara (Irish Sea Fisheries Board)
CE: Capillary electrophoresis
DAD: Diode array detector
FAO: Food and Agriculture Organisation
FOSHU: Foods for Specific Health Use
HA: Hippuric acid
HGG: Hippuryl- glycine- glycine
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HPLC: High performance liquid chromatography 
HHL: Hippuryl-L-histidyl-L-leucine 
HL: Histidyl- leucine
ICES: International Council for the exploration o f the Seas
id: Internal diameter
kDa: kilo Dalton
LIF: laser-induced fluorescence
LOD: Limit o f detection
LOD: Limit o f quantification
MALDI-TOF: Matrix assisted laser desorption/ionisation- time o f flight
MS: Mass spectrometer
NEA: Northeast Atlantic mackerel
PB: phosphate buffer
PEP: prolyl endopeptidase
PO: prolyl oligopeptidase
List of Abbreviations
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PPT: parts per trillion
PSI: pounds per square inch
RP: Reverse phase
RPM: revolutions per minute
RSD; Relative standard deviation
SD; Standard deviation
SHRs: spontaneously hypertensive rats
WHO: W orld Health Organisation
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When Angiotensin I is cleaved by Angiotensin-I-converting enzyme (ACE-I) 
which is present on the surface o f vascular endothelial cells, Angiotensin II is 
formed. This is responsible for arteriolar vasoconstriction, which increases 
blood pressure. Bradykinin, a known vasodilator is also degraded by ACE-I and 
this also contributes to an increase in vasoconstriction. Control o f ACE-J by 
ACE-I inhibitors therefore increases bradykinin and prevents Angiotensin II 
formation which lowers blood pressure.
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Aromatic or branched side chain residues are preferred. Aliphatic, basic and 
aromatic residues are preferred in the penultimate positions and aromatic, 
proline and aliphatic residues are preferred in the ultimate position. The 
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acids and is preferred as one o f the C-terminal amino acid residues, The 
branched aliphatic amino acid residues are preferred at the N-terminal end o f the 
AC'E-I-inhibitory peptide with the exception of Arginine I. Underlined 
sequences have previously been identified as ACE-I-inhibitors, (Source: Hayes 
et al., 2007).
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1. Literature review
1.1 Introduction
In recent years, over-exploitation o f fishery resources has become a major concern 
worldwide. According to data published by the Food and Agriculture Organisation (FAO, 
2008), approximately 77% o f the 143.6 million tons o f fish and shellfish caught in 2006 was 
used for human consumption. The remaining processing leftovers which, includes 
trimmings, fins, frames, heads, shells, skin and viscera are normally used for the production 
o f fishmeal, fish oil, fertiliser, fish silage and animal feed. These by-products may be 
identified as processing leftovers that are not normally saleable but which can be recycled 
after treatment. Annual discard from marine capture and aquaculture fisheries worldwide is 
estimated to be approximately 20 million tonnes per year (FAO, 2008), In Ireland, figures 
from An Bord Iascaigh Mhara (BIM; The Irish Sea Fisheries Board), estimated that 63,786 
tonnes of marine processing waste were produced nationally in 2000, 45% of which arose 
from the northwest region (Pfeiffer, 2003), European legislation, Council Directive 
1999/31/EC o f 26 April 1999 on the landfill o f waste, has set specific targets for the amount 
o f municipal waste allowed for disposal at landfills. Landfill is also a costly waste disposal 
option for the seafood industry. Generation o f substantial quantities o f marine processing by­
products is therefore both an environmental and economic concern for the seafood processing 
sector (Kim and Mendis, 2006) As a result, there has been increased interest in exploring 
the possible uses o f fish by-products, or rest raw material, so that they become viewed as a 
potential resource due to their valuable protein and lipid content and sugars and minerals 
instead o f a waste problem, (Akihisa et al., 2004; Bruyere et al., 2004; Kelley, 2001; Larsen 
et al., 2000; Yokoyama et al., 1992),
Proteins from food are sources o f  numerous bioactive peptides wi th anti-hypertensive, opioid, 
anti-thrombotic and immune-modulating activities. The use o f fish processing by-products as 
substrate provides a novel approach for the potential discovery o f high-value bioactive 
products. In the past twenty years, an emerging area o f research is the identification of 
bioactive compounds that may be present in marine by-products. Bioactive compounds are 
described as ‘food-derived com ponents’ that, in addition to their nutritional value, exert a 
physiological effect in the body’ (Vermeissen et al., 2004).
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This thesis reviews current information on ACE-I-inhibitory and PEP inhibitory peptides. It 
also details the potential health benefits o f these peptides and their potential for use as 
functional food components. The thesis examines the isolation and characterisation strategies 
used to obtain these inhibitors from natural sources, with a focus on marine substrates. 
Emphasis for this thesis is placed on identification o f  bioactive peptides from mackerel and 
whelk waste, two products identified by a local large scale fish processing company (Per. 
comm. Errigal Fish Company Ltd., Carrick, County Donegal). The development o f these 
technologies in search o f novel bioactive peptides for human exploitation from marine 
processing wastes will bring increased value to what is today considered an environmental 
waste problem,
1.2 Mackerel and W helk life history and habitats
Atlantic Mackerel (Scomber scombrus) is an abundant, fast swimming, migratory pelagic 
schooling species found on both sides o f the North Atlantic Ocean. The mackerel in the 
eastern Atlantic has traditionally been divided into three spawning groups named according 
to their spawning areas: Southern (Gibraltar to the Bay o f Biscay), Western (Bay o f Biscay to 
Scotland), and North Sea and these are managed as one stock; the Northeast Atlantic 
Mackerel (NEA), The Northeast Atlantic (NEA) mackerel supports a very valuable fishery, 
with landings that have ranged between 470,000 and 820,000 tons since the mid-1990s 
(ICES, 2008), Mackerel processing and waste data supplied by the Errigal Fish Company 
Ltd., Carrick, Co. Donegal up to the end o f 2008 detailed annual processing input o f 7,000 
metric tons with 2,800 metric tons o f waste generated as a result.
Mackerel are abundant in cold and temperate shelf areas with a rapid growth cycle and a life 
span of approximately 17 years. They are opportunistic feeders and prey most heavily on 
crustaceans such as copepods, krill, and shrimp. They also eat squid, and some fish and 
ascidians. Mackerel also play an important ecological role by feeding on zooplankton and 
on the pelagic juvenile and larval stages of a number o f commercially important fish stocks. 
Mackerel may grow to a maximum length o f 66 cm, although fish >50 cm are uncommon; 
they reach reproductive maturity when they are between two and three years old. Mackerel 
are batch spawners with females shedding their eggs in some twenty batches during the 
course o f the spawning season which is between February and July. Eggs generally float in 
the surface water and hatch in four to seven days, depending on water temperature (ICES, 
1990).
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Atlantic mackerel are iridescent blue green above with a silvery white underbelly (Figure
1.1). They have twenty to thirty wavy black bars that run across the top half o f their body, 
and there is a narrow dark streak that runs along each side from pectoral to tail fin below the 
bars. Their body is spindle shaped, tapering at both ends. They have two separate large 
dorsal fins that are grey or dusky. The pectoral fms are black or dusky at the base, and the 
tail fin is grey or dusky.
Figure 1. 1. Scomber scombrus, Atlantic mackerel,
Mackerel are preyed upon heavily by dolphins, whales, dogfish, hake, Atlantic cod, bluefish, 
and striped bass, swordfish, red hake, Atlantic bonito, blue-fm tuna, blue shark, sea lamprey, 
and short-fin mako and thresher sharks (ICES, 1990).
The common whelk, Buccinum undatum  L. 1758, is a large edible gastropod mollusc (Figure
1.2) common in the sub-tidal range to 200m depth in on both sides o f the Atlantic, from 
Canada south to New Jersey in North America and in Europe from Norway to south- west 
France. Fahy et al, (2000) reported the onset o f maturation in Irish Sea whelk at between 60 
and 70 mm total length and around 6-8 yrs. The shell has 7-8 whorls with spiral ridges and is 
yellowish brown with irregular light and dark spiral areas. The aperture is broadly oval 
tapering to a point with a short wide siphonal canal leading from the base o f aperture. Whelk 
shell structure alters in response to a variety o f factors that include latitude, environment, sex 
of the individual and predation pressure. Shell thickness in Buccinum  alters in response to 
the occurrence of large decapod predators. Irish inshore waters support morphologically 
easily distinguishable stocks o f whelk and the more heavily armoured ones co-occur with 
high densities o f brown crab (Fahy et al., 2005). Predators o f B. undatum  include several 
invertebrate species such as crabs, lobsters, and starfish.
The major European countries exploiting whelk include Belgium, France, Iceland, Ireland,
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and the UK with the main traditional markets in Europe found in England, France, and the 
Netherlands (Nasution and Roberts, 2004). The fishery for this species boomed in the 1990s 
with an increase in demand from the Far East, mainly South Korea (Fahy et al., 2005). In 
2003, 672 tons o f whelks were landed from the Cape grounds in Co. Donegal in six locations 
o f which the largest were M alin and Greencastle. Landing data was provided by Errigal Fish 
Company Ltd., Carrick, Co, Donegal and in the period 2008 to present whelk input for 
processing by the company was 4,000 metric tons per annum which results in the generation 
o f 1,700 metric tons o f waste material.
Figure 1. 2. Buccinum undatum  the common Irish whelk
1.3 Function of ACE-I and PEP inhibitory peptides
Hypertension is one o f the m ost common cardiovascular diseases worldwide. Data gathered 
by Kearney et al. (2005) demonstrated that over 25% of the adult population nearly 1 billion 
people worldwide suffer from hypertension. Hypertension is a risk factor for arteriosclerosis, 
stroke, myocardial infarction and end-stage renal disease (Kearney et a l., 2005). The 
prevalence o f high blood pressure increases with age, affecting approximately 65% o f the 
population in developed nations within the age group 65-74 years (Duprez et al., 2002). The 
World Health Organisation (WHO) estimates that by 2020, heart disease and stroke will have 
surpassed infectious diseases to become the leading cause o f  death and disability worldwide 
(Lopez and Murray, 1998). Diet therapy and lifestyle modifications are the two most 
important tools commonly employed to effectively lower blood pressure (Hermansen, 2000).
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Therefore, any food component that has the ability after digestion to reduce blood pressure in 
humans is a potential candidate for use in the prevention and/or treatment o f cardiovascular
disease,
Angiotensin-I converting enzyme (ACE, EC 3,4,15.1) belongs to a class o f zinc proteases and 
is widely distributed in mammalian tissues. It is predominantly found as a membrane-bound 
ecto-enzyme in the vascular endothelial cells o f the lungs and other organs such as the brain, 
heart, liver, kidney, intestine and placenta as well as in several other cell types including 
absoiptive epithelial, neuroepithelial, and male germinal cells (Riordan, 2003), ACE-I 
catalyses the formation o f  the potent vasoconstrictive and salt-retaining octapeptide 
angiotensin II with the amino acid sequence Asp-Arg-Val-Try-Ile-His-Pro-Phe, from the 
decapeptide angiotensin I, Asp-Arg-Val-Try-Ile-His-Pro-Phe-His-Leu, by liberating the C- 
terminal di-peptide His-Leu in the Renin-Angiotensin system (Yang et al., 1971) (Figure
1.3). ACE-I also inactivates the vasodilative peptide bradykinin in the kallikrein-kinin 
system (Meisel et al., 2006) (Figure 1.3). Additionally ACE-I functions as a stimulant for the 
release o f aldosterone in the adrenal cortex (Silvestre et al., 1999), Therefore ACE inhibitors 
can be expected to reduce and regulate blood pressure and fluid and salt balance in mammals 
(Figure 1,3),
Prolyl endopeptidase (PEP, EC 3.4,21.26) also known as prolyl oligopeptidase (POP or PO), 
is a highly conserved serine protease enzyme that cleaves peptide bonds at the carboxyl side 
o f Proline residues in proteins with a relatively small molecular weight (30 amino acids in 
size) containing the recognition sequence X-Pro-Y, where X is a peptide or protected amino 
acid and Y is either an amide, a peptide, an amino acid, an aromatic amine or an alcohol 
(Walter et a l , 1980), PEP is widely distributed in mammalian tissues and was found in over 
20 human tissue types with the highest activity found in skeletal muscle and in the human 
brain (Kalwant and Porter, 1991), In the brain, the highest PEP activity was found in the 
cortices (Irazusta et al., 2002), PEP has also been isolated from various tissues such as rat 
(Rupnow et ah, 1979), lamb (Yoshimoto et al., 1981) and bovine brain (Yoshirnoto et al., 
1983) as well as pig liver (Moriyama et al., 1988). PEP has also been found in the bacterium 
Flavobacterium meningosepticum  (Chevallier et al., 1992) and in the mushrooms Lyophilium  
cinerascens (Yoshimoto et al., 1988) and Agaricus bisporus (Sattar et al., 1990) as well as 
Spinach thylakoids (Kuwabara, 1992).
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Renin-Angiotensin System
Figure 1. 3, A product o f renin-cleaved angiotensinogen is the decapeptide Angiotensin I. 
When Angiotensin I is cleaved by Angiotensin-I-converting enzyme (ACE-I) which is 
present on the surface of vascular endothelial cells, Angiotensin II is formed. This is 
responsible for arteriolar vasoconstriction, which increases blood pressure, Bradykinin, a 
known vasodilator is also degraded by ACE and this also contributes to an increase in 
vasoconstriction. Control of ACE by ACE-I inhibitors therefore increases bradykinin and 
prevents Angiotensin II formation which lowers blood pressure.
PEP was first isolated as an oxytocin-inactivating enzyme from the human uterus and was 
found to hydrolyse the prolyl-leucyl bond in oxytocin (Walter et al., 1971), In vitro, PEP 
plays an important role in the degradation o f  biologically active peptide hormones and 
neuropeptides that contain proline and PEP is known to cleave the peptides angiotensin I and
II, neurotensin, vasopressin, bradykinin, thyroid releasing honnone and substance P (Burbach 
et al., 1983, De Weid et al., 1984, Rennex et al., 1991, Welches, et al., 1993, Yoshimoto et 
al., 1983).
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Previous studies suggested that prolyl endopeptidase could be related to neurodegeneration 
and disturbances in memory and cognition (Husain and Nemeroff, 1990, Rossor et al., 1986), 
Recently, research has suggested that PEP functions in relation to mood disorders by acting 
as a regulator o f inositol phosphate (InsP) signalling thereby modulating the effect o f inositol 
depleting drugs such as Lithium in the treatment o f bipolar disorder (BD) (Williams, 2004), 
Amyloid (3 plaques are commonly found in the brain o f A lzheimer’s disease patients. RoPner 
et al. (2005) studied the expression o f PEP in adult and aged transgenic mice, which 
expressed amyloid (3 plaques. In the hippocampus o f adult mice studied, PEP expression was 
increased in parallel with memory deficits but before appearance o f  the amyloid (3 plaques. 
Altered serum PEP activity has also been reported in many psychiatric disorders, and 
abnormal levels o f PEP activity have been found to be significantly higher in Alzheimer’s 
patient brains than in control patients (Aoyagi et al., 1990, Ichai et al., 1994, Maes et al.,
1995). In addition, lowered serum PEP activity was identified in bulimia nervosa and 
anorexia nervosa patients (Maes et a l ,  2001). Furthermore, PEP activity was increased by 
antidepressants and increased serum PEP activity was found in patients with biopolar 
disorder (manic) and in schizophrenic patients and persons with stress induced anxiety such 
as Post- Traumatic Stress Disorder (PTSD) (Maes et al., 1998, Maes et al., 1999). Altered 
PEP activity has also been observed in autism spectrum disorders (Momeni et al., 2005), 
PEP-like immunoreactivity has also been detected in the hippocampus o f senescence- 
accelerated mice (Fukunari et al., 1994)^"
Inhibitors o f  PEP (POP) Tc80 have potential as anti-protozoal drugs specifically against the 
agent o f Chagas disease, Trypanosoma cruzi (Bastos et al., 2005) which is prevalent in Latin 
America, Inhibitors of PEP may improve memory by blocking the metabolism o f 
endogenous neuropeptides (Tezuka et al., 1999). There are two known kinds o f PEP 
inhibitors, peptidic inhibitors and non-peptidic inhibitors (Amor et al., 2004). Peptidic 
inhibitors contain an electrophilic centre such as an alpha-keto beta-amide group and this 
group is considered to be an active centre. Non-peptidic inhibitors contain either a catechol 
or pyrogallol group which is believed to be responsible for PEP inhibition (Fan et al., 1999). 
As PEP inhibitors have been identified in natural plant extracts and wine and green tea PEP 
inhibitors from natural sources could help in modulating PEP activity through dietary intake 
and the mental disorders associated with PEP.
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1.4 Sources of ACE-I and PEP inhibitory peptides
ACE-I- inhibitory peptides have been isolated from various marine proteins such as Heshiko, 
a fermented mackerel product (Itou and Akahane, 2004), skipjack tuna muscle (Kohama et 
al., 1988), sardine muscle (Bougatef et al., 2008), shark meat (Wu et al., 2008), Alaskan 
Pollack skin (Byun and Kim, 2001), marine shrimps (Wang et al., 2008a), pacific hake 
(Cinq-Mars and Li-Chan, 2007) and salmon chum (Ono et al., 2005) (Table 1.1). Theodore 
et al. (2007) generated a catfish protein hydrolysate containing ACE-I-inhibitory activity 
using the enzyme preparation Protamex®. This study found that protein hydrolysates o f 
purified catfish protein had strong ACE-I-inhibitory activity. Suetsuna (2002) identified the 
ACE-I-inhibitory peptides Ile-Ala-Glu, Ile-Val-Glu, Phe-Glu, and Ala-Leu-Ala-Phe-Glu from 
pearl oyster and clam. Jae-Young et al. (2005) identified the ACE-I-inhibitory peptide Glu- 
Val-Met-Ala-Gly-Asn-Leu-Tyr-Pro-Gly from Mytilus edulis. A number o f ACE-I inhibitory 
peptides have also been isolated from soy and chicken breast proteins (Ariyoshi, 1993, 
Ringseis et al., 2005, Saiga et al., 2006), garlic (Suetsuna, 1998) and wine (Pozo-Bayon et 
al., 2007). Eggs have also been found to contain compounds with antihypertensive functions 
such as ovokinin, derived from an enzymatic digest o f ovalbumin (Fujita et al., 1995, Matoba 
et al., 1999). Also hydrolysis o f a-zein, which is a maize endosperm protein, by thermolysin 
yields 3 strong ACE inhibitors (Miyoshi et al., 1995). Additionally potatoes and their by­
products/wastes have also been found to contain high potency ACE-I inhibitors after 
controlled hydrolysis (Pihlanto et al., 2008).
Synthesised chemical drugs such as Captopril®, Enalapril®, Alacepril® and Lisinopril® are 
extensively used medications in the treatment and prevention o f hypertension. However, 
these drugs often cause side-effects in the patient, such as a persistent dry cough, angio- 
oedema, taste disturbances, increased potassium levels, reduced renal function and skin 
rashes (Atkinson and Robertson, 1979, Dicpinigaitis, 2006). Naturally sourced ACE-I- 
inhibitors raise the possibility that hypertension could be modulated through dietary intake.
Few PEP inhibitors are from natural plant sources and they are usually chemically 
synthesised structures. However, naturally occurring PEP inhibitors have been identified in 
red wine (Yanai et al., 2003), plant extracts used in herbal or traditional medicines (Fan et 
al., 2001), green tea (Kim et al., 2001), and peptides isolated from bovine brain (Ohmori, et 
al., 1994). The inhibitory activities o f plant sourced PEP inhibitors are low and their binding 
modes are generally not known. A wide variety o f  PEP inhibitors have been described in
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scientific literature and patents (Jarho, 2007), Most o f the published inhibitors are 
chemically synthesised, substrate-like inhibitors that are based on the N-acyl-L-prolyl- 
pyrrolidine structure and their binding mode is known,
A study by Amor et al. (2004) isolated PEP inhibitory compounds from Syzygium  
samarangense (Blume) Merr & Perry (Myrtaceae) which is a plant native to the Philippines 
and known as “makopa” (Amor et al., 2004), Furthermore, Ginkgo biloba leaves were 
examined for their anti-amnesic constituents/PEP inhibitors and results showed significant 
PEP inhibition, PEP activity-guided fractionation and column chromatography o f the MeOH 
extracts o f G, biloba leaves resulted in the isolation of 6-(10'Z-heptadecenyl) salicylic acid 
(Lee et a l,, 2004). The Tibetan folk medicine Rhodiola Radix originates from several alpine 
Rhodiola (R.) plants and is used as a haemostatic, tonic and contusion. The anti-fatigue, anti­
anoxia effects o f  this plant have also been reported. Fan et al. 2001 found that methanol 
extracts o f Rhodiola sachalinensis also showed potent PEP inhibitory activity, The PEP 
inhibitory activities o f Bangladeshi Indigenous Medicinal plants including Emblica 
officinalis, Zingiber officinale and Myristica malabarica were examined by Khanom et al. 
(2000), Tezuka, et al. (1999) examined the PEP inhibitory activities o f a number o f crude 
Chinese and Indian drug extracts, This study found that water-extracts o f Rhodiola sacra 
(IC50, 0,77 pg/ml) and the methanol-extracts o f Lycopodium clavatum  (IC50, 1.3 (ig/ml), 
Paeonia lactiflora var. trichocarpa (IC50, 5,7 (J.g/ml), Paeonia veitchii (IC50, 2,4 (ig/ml) and 
R. sacra (IC50, 0.67 (xg/ml) showed strong PEP inhibitory activities, In addition, Tezuka et 
al. (1999) examined the PEP inhibitory activity o f eleven compounds from Salvia deserta, 
and found that in addition to a catechol group alpha-hydroxy-para-quinone group may be 
related to the PEP inhibition. The PEP inhibitory activity of unsaturated fatty acids was also 
examined by Park et al. (2006). This study looked at the effects on PEP activity o f mono- 
and poly-unsaturated fatty acids found in vegetable seeds and fatty fish.
A number o f PEP inhibitors have been chemically synthesised as anti-amnesiac drugs and an 
example o f one such inhibitor is S 17092 which can inhibit both chemically induced amnesia 
and spontaneous memory deficits in humans (Morain et a l,  2002). PEP inhibitory peptides 
have been found in a variety of food sources as outlined in Table 1.2, PEP inhibitory 
peptides associated with red wine produced from Cabernet Sauvignon grapes were 
characterised by Yanai et al. (2003), Two peptides were separated by reverse phase High 
Pressure Liquid Chromatography and subsequently purified using gel filtration techniques
and their amino acid structures determined as Val-Glu-Ile-Pro-Glu and Tyr-Pro-Ile-Pro-Phe 
(Yanai et al., 2003), PEP inhibitory peptides have also been identified from sake and sake 
cake (Saito et al., 1997), salmon, cod, trout and cheese hydrolysates (Sorensen et al., 2004, 
Yoshikawa et al., 2000) and also from synthetic peptide fragments o f  human p-casein (Asano 
et al., 1991), PEP inhibitory compounds have also been found in sulphated 
chitooligosaccharides (Je et al., 2007), in a methanolic extract o f green lea (Kim et al., 2001), 
and in the roots o f the plant Lindera strychnifolia F. Vill (Kobayashi el al., 2002),
Natural plant derived ACE-I-inhibitors and PEP inhibitors have lower bioactivities in vivo 
than synthetic PEP and ACE-I-inhibitory drugs but also display no harmful side-effects 
(Riordan, 2003) and are generally lower in cost (Vermeirssen et al., 2004), As a result, the 
search for bioactive peptides from a variety of different food sources has become a major 
area o f research with potential for the functional foods sector
Products exploiting the potential o f bioactive peptides are already on the market or under 
development by food companies, Examples of food products on the market containing 
ACE-I inhibitory peptides are Ameal S (Calpis Co., Ltd,, Japan), a sour-milk product in tablet 
form which contains 2 potent ACE-I inhibitors, VPP [P-casein f(84-86)] and IPP [P-casein 
f(74-76)] (Nakamura et al., 1995) and Peptide Soup (The Nippon Synthetic Chemical 
Industry Co., Ltd., Japan), which is a Katsuobushi oligopeptide obtained from thermolysin 
digested Katsuobushi (dried bonito) (Yokoyama et al., 1992).
1.5 Derivatisation of ACE-I and PEP inhibitory peptides
The experimental strategy for the derivatisation of ACE-I and PEP inhibitory peptides is 
outlined in Figure 1.4. This approach employs the proteolysis o f a protein source using 
bioassay-guided fractionation and separation o f peptides followed by chemical elucidation 
and in vivo assays o f active peptide fractions. Three key factors are important in relation to 
the release o f peptides with bioactivities such as ACE-I and PEP inhibition. These three 
factors are (a) the nature o f the matrices, (b) the choice o f protease and (c) the extent o f 
hydrolysis (Guerard et al., 2010).
Guerard et al. (2010) extensively reviewed this topic and concluded that numerous substrates 
are potential candidates to be transformed into bioactive hydrolysates containing bioactive
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T able 1.1. Examples o f ACE inhibitory peptides derived from marine sources
Origin Hydrolysis Peptide Sequence IC jw (pM) Reference
Sardine muscle
Dried Skipjack luna musclc
Alkaline proteose 
Tlicnnolysiu
Lys-Trp 1.63
Lcu*Ly s-Pra-M ct-Asit 2.4 
Pro-Thr- His-Ile-Lys~Trp*Gly-Asp 2.0
J ?  < APhc-Leu A  13.6 
Lcu-Phc 383.2
. d C r  ^
Cys-Plw 1.96 
Glu-Try 2.68 
Phe-Glu 1.45
Matsufuji ef tit. (1994)
Fuji 18 & Yoshikawa (1999)
Skipjack Tuna musclc 
Salmon chum musclc
Shark meat
Acid cxtraci
Thermolysin
Pro tease SM980II
Kohama etat, (1988) 
Ono et <?/, (2005)
Wu eto l. (2008)
Shrimp Acutes chinensis L  ferment um SM 605 Asp-Pro 2.15 
Gly-Thr-Gly 5.54 
Scr-Thi 4.03
Want; et al (2008b)
Oyslctf protein Pepsin Vtil-Val-Tyr-Pro-Trp-Tlir-Gln-Arg-Plie 66.00 Wang et at. (2008a)
Alaska Pollack skin Aicalasc. promise E 
& collngcnase
Gly-PioM ei 17.13 
Gly-PfMJM 2.60
Byun and Kim (2001)
Anchovy fermented fish saucc Unknov.ii L.y*-Pn> 22.00 tchimura et qL (2003)
Algae prole in waste Pepsin VsMilu-Cys-Tyr-Gly-Pro-Asn - Arg-Pl'O-G til-Phc 29.60 Sheih ct at. (2009)
Wukatnc (Uiularja pimuUifhhi) Proieasc S ‘’Ainaiiu" Ilc-Tyr 6.10 
Vul-Tm 3.30 
lle-Trn ‘ -50
Sato et of. (2002)
T abic 1.2. Examples o fPE P  inhibitory peptides derived from various sources
Origin & hydrolysis Peptide Sequence ICwfjiM ) Reference
Cod, salmon and trout hydrolysed with porcine trypsin 
Cubcrttei Sauuijftioa rad ivtnc
N-A-
Val-Olu-llc-Pro-Cilu
Tiy-Pro-llc-Pro-Phc
His-Leu-Pro-Pro-Pro-Val
.*• 0  ^  
lle-Tyr-Pro-Phc-Val-Glu Pro-llc
Ser-Pro-PlK-Trp- A sn -11 e-Asn-Ala 
Leu-Ser-ProPx' i ip Asn-llc-Asn-Ala 
Lcu-l.cu-Sei-Pro-Pht.--lrp-Ash lie-Asn-Ala
N/A
17,00
Sorensen el al. (2004) 
Vanin el al, (2003)
y-zein hydrolysed by subtilism (Carlsberg)
87.80
80.00 Maruyunta el al (1992)
Synthetic peptide fragments of'human p-casein (region49-59) 
Sake cake hydro! ysatc by pepsin
8.00
42.80
J.9.00
24.30
Asano et al. (1991) 
Saito el a! (1997)
Soke hydrplysate by pepsin pGln - Leu-Phc - A sn-Pro -Ser-Thr-Asa-PtO-T rp-His-Scr-Pro
pGlu-Leu-PhcAsii-Pro-Scr-Thr-Asn-Pro-Trp-Hit-Scr-Pro-Arg
pCilu-Lcu-Phe-Ctly-Pro-Asn-Val-Asn-Pro-Trp-His-Asn-Pro-Arg
24,30 
14 10 
11 SO
Saito ef of, (1997)
Bovine brain Mcl-Prp-Pro-Pro-l cu-Pra-Aln-Arg-Val-Asp-Phe-Ser-l.cu-Alii 
Cily-Ala-Leu-Asn
38.40 Ohmori el al. (1994)
*'Nut Available
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peptides as long as they are available in sufficient quantities, are o f  good quality in terms of 
freshness and weak microbial contamination (Guerard et a l,  2008), They also characterised 
the most popular proteases for use in by product solubilisation and found that Alcalase®, 
Flavourzyme®, Neutrase®, and 258 Protamex TM are the most commonly used enzymes for 
by-product solubilisation (Guerard et al., 2008),
The isolation of bioactive peptides typically involves the hydrolysis o f the protein of choice 
with different proteolytic enzymes alone or in combination with GRAS micro-organisms. 
Hydrolysates can then be pre-screened for bioactivity using standard in vitro inhibition 
studies. The most commonly used method for the detection o f ACE I-enzyme inhibitory 
activity is based on the Cushman and Cheung protocol (Cushman & Cheung, 1971), whereas 
for PEP inhibitor identification the methods employed are generally based on a protocol 
developed by Yoshimoto et al. (1979), Positive hydrolysates can then be sub-fractionated 
using a range o f fractionation and chromatographic techniques to isolate, purify and 
concentrate the bioactive peptide fraction with activity determined by in vitro assays. The 
peptide structure can then be elucidated using Mass Spectrometry (MS) and Nuclear 
Magnetic Resonance (NMR) elucidation methods. In vivo assays are then used to determine 
the bioavailability o f the isolated peptide fraction in an animal and subsequently a human 
subject.
Proteases o f  microbial origin can potentially release bioactive peptides (Gobbetti et al.,
2002). Given the highly proteolytic nature o f LAB such as Lactococcus lactis (Matar et a l,
1996) and Lactobacillus helveticus it is not surprising that their use as microbial catalysts for 
the generation o f bioactive peptides has been investigated (Rokka, 1997). Previously ACE-I 
inhibitory peptides were released from whey and casein following fermentation with different 
strains o f lactic acid bacteria (LAB) followed by hydrolysis with digestive enzymes (Mizuno 
et a l ,  2004), Screening for proteolytic activity from a bacterial culture collection is 
performed using suitable agar plates supplemented with skim milk (Pailin et al., 2001, Van 
der Berg et al., 1993). Proteolytic strains are recognised by zones of clearing using this 
method, Other methods used to identify GRAS proteolytic strains include HPLC breakdown 
analysis o f milk proteins such as whey and casein compared to standards such as bovine 
serum albumin (BSA) (Minervini et a l ,  2003),
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ACE-I and PEP inhibitory activity o f bioactive peptides is first determined using in vitro 
inhibition studies (Cushman & Cheung, 1971, Yoshimoto et al., 1979) in order to obtain lead 
candidates for inhibitory activity. ACE-I and PEP inhibitory activity is determined by 
reference to positive inhibitors such as Captopril®, a synthetic ACE-I inhibitor, or Val-Glu- 
Ile-Pro-Glu, a known PEP inhibitor. The Cushman and Cheung assay protocol for ACE-I 
inhibition measurement is based on the hydrolysis o f hippuryl-histidyl-leucine (HHL) by 
ACE-I to give hippuric acid (HA) and histidyl-leucine as products and subsequent 
quantification o f HA release. The HA is extracted into ethyl acetate and quantified by 
measuring the absorbance in a spectrophotometer at 228 nm  (Roy et al., 2000). This method 
requires several steps and the HA can be contaminated with ethyl acetate which also absorbs 
strongly at 228 nm unless fully evaporated using nitrogen evaporation.
Alternative rapid and sensitive High Pressure Liquid Chromatography (HPLC) methods for 
direct analysis o f the ACE-I reaction mixture through complete separation o f HHL and HA 
have been developed (Wu et al., 2002). Furthermore, various high throughput and rapid 
screening capillary electrophoresis (CE) methods to determine the ACE-I-inhibitory values 
for bioactive peptides have also been developed (He et al., 2007).
The CE and HPLC methods were compared and the CE method was found to be faster, more 
automated and needed fewer samples, substrates and other accompanying reagents which 
suggested that the CE method was more suitable for high throughput screening o f protein 
hydrolysates with ACE-I-inhibitory activity. The HPLC method is thought to have better 
reproducibility than the CE technique, A high-throughput method was recently developed for 
screening ACE-I inhibitors, where the free HA is mixed with pyridine and benzene sulfonyl 
chloride. This mixture produces a yellow colour with a Xmax at 410 nm, which is directly 
proportional to the released HA. This investigation found that there was good correlation 
between the IC50 values o f Captopril® obtained by the newly developed colorimetric method 
and the commonly used HPLC technique (Jimshena & Gowda, 2009).
Bioactive peptides are typically concentrated by molecular weight cutoff (MWCO) and/or 
ultra-filtration through 3 and lOkDa membrane filters as ACE-I-inhibitory peptides are 
usually between 2-30 amino acids in size (Erdmann et al., 2008) and most PEP- inhibitory 
peptides discovered to date are usually between 4- 18 amino acids in size. Synthesis and 
application of the first fluorogenic substrate, N- carbobenzoxyglycylprolyl-4-
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Figure 1.4. Experimental strategy for the derivatisation o f ACE-I and PEP inhibitory 
peptides,
methylcoumarinyl amide (Z-Gly-Pro-MeCouNH) for the determination o f PEP was first 
reported by Yoshimoto et al. (1979). In-vivo testing demonstrated that high PEP activity 
levels were observed in the testis, liver and skeletal muscle o f rats. Activity in human body 
fluids was also tested for levels o f PEP activity and semen was found to possess the highest 
cleaving activity (Yoshimoto et al., 1979).
27
In- vitro PEP inhibitory activity may be determined by the assay method described by Yanai 
et al. (2003). This is a modified version o f the PEP assay described by Yoshimoto et al. 
(1979). A phosphate buffer (pH 7.0), PEP from Flavobacterium meningosepticum  and the 
test sample in methanol are mixed and incubated at 30°C for 5 min, and the reaction started 
by the addition of 2 mM Z-Gly-Pro-pNA (in 40% 1,4-dioxane). After incubation at 30°C for 
10 minutes, a stop solution (1 M HC1) is added and the absorbance o f the solution is 
measured at 410 nm. Suitable positive and negative controls are used.
1.5.1 Principles of capillary electrophoresis (CE)
Capillary electrophoresis techniques are routinely employed to separate molecules with high 
resolution and the method has been extended to a large diversity o f chemical compounds as 
the separation is based on the number of theoretical plates, which may be in excess o f 
1,000,000 (Lauer and Rozing, 2010). Other advantages o f CE are its low consumption o f 
samples and reagents, use o f aqueous solutions, little sample pre-treatment required, 
compatibility with auto-samplers, easy cleaning and conditioning o f capillaries. There are a 
number o f different modes o f electrophoretic separation that may be coupled to diverse 
detection methods in the same equipment. These methods include UV detection, laser- 
induced fluorescence (LIF) excitation, electrochemical detection and mass spectrometry.
Capillary electrophoresis is a technique in which molecules are separated in narrow 
capillaries under an applied electric field (Lauer and Rozing, 2010), The electric field rather 
than gas or solvent flow moves the molecules through the capillary. Molecules in solution 
will then be separated based on their electrophoretic mobility. The electrophoretic mobility 
o f an object in an applied electric field is determined by the charge on the molecule, the 
frictional coefficient o f the molecule, which depends on size and shape, and the viscosity o f 
the solvent:
(6 m j)
where /de= the velocity o f the particle in an applied field, q = ion charge, r\ = solution 
viscosity, r = ion radius.
The velocity of the particle in an applied field is pe times E, where E is the applied 
field. Hence small highly charged species have high mobilities and large minimally charged
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species have low mobilities, The simplest CE method is capillary zone electrophoresis (CZE), 
a method by which molecules ions or particles are separated solely by their electrophoretic 
mobility. The simplification that holds true for this technique is that the velocity is 
proportional to the charge to mass ratio. The capillaries are usually made o f silica, hi 
uncoated capillaries at pH greater than 4 the SiOH groups are ionized to SiO'. This leads to a 
phenomenon called electroosmotic flow (EOF), An overview of a CE system illustrating a 
cross-section o f the capillary is shown in Figure 1.5.
A fundamental constituent o f CE operation is electroosmotic, or electroendosmotic flow 
(EOF). EOF is the bulk flow o f liquid in the capillary and is a consequence o f the surface 
charge on the interior capillary wall. The EOF results from the effect o f the applied electric 
field on the solution double-layer at the wall (Figure 1,6). The EOF controls the amount of 
time solutes remain in the capillary by supeiposition o f flow on to solute mobility. This can 
have the effect o f altering the required capillary length, but does not affect selectivity. Under 
aqueous conditions most solid surfaces possess an excess o f negative charges. This can result 
from ionization of the surface (that is, acid-base equilibria) and/or from adsorption o f ionic 
species at the surface, For fused silica both processes occur, although the EOF is most 
strongly controlled by the numerous silanol groups (SiOH) that can exist in anionic form 
(SiO‘) (Figure 1.6), Counterions (cations, in most cases), which build up near the surface to 
maintain charge balance, form the double layer and create a potential difference very close to 
the wall. This is known as the zeta potential. When the voltage is applied across the capillary 
the cations forming the diffuse double-layer are attracted toward the cathode, Because they 
are solvated their movement drags the bulk solution in the capillary toward the cathode. The 
zeta potential is essentially determined by the surface charge on the capillary wall. Since this 
charge is strongly pH dependent, the magnitude o f the EOF varies with pH, At high pH, 
where the silanol groups are predominantly deprotonated, the EOF is significantly greater 
than at low pH where they become protonated. Depending on the specific conditions, the 
EOF can vary by more than an order o f magnitude between pH 2 and 12 (Lauer and Rozing, 
2010).
A unique feature o f EOF in the capillary is the flat profile o f the flow. Since the driving force 
o f the flow is uniformly distributed along the capillary (that is, at the walls) there is no 
pressure drop within the capillary, and the flow is nearly uniform throughout. The flat flow
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Figure 1. 5. An overview o f a CE system with capillary cross-section.
(Source: http://www.beckmancoulter.co.jp/product/product01/cap_zone.html)
profile is beneficial since it does not directly contribute to the dispersion o f solute zones. This 
is in contrast to that generated by an external pump which yields a laminar or parabolic flow 
due to the shear force at the wall. Another benefit o f the EOF is that it causes movement of 
nearly all species, regardless o f charge, in the same direction. Under normal conditions 
(negatively charged capillary surface), the flow is from the anode to the cathode. Anions will 
be flushed towards the cathode since the magnitude o f the flow can be more than an order o f 
magnitude greater than their electrophoretic mobilities. Thus cations, neutrals, and anions can 
be electrophoresed in a single run since they all “migrate” in the same direction. This process 
is depicted in Figure 1,5. Here, cations migrate fastest since the electrophoretic attraction 
towards the cathode and the EOF are in the same direction, neutrals are all carried at the 
velocity o f the EOF but are not separated from each other, and anions migrate slowest since 
they are attracted to the anode but are still carried by the EOF toward the cathode (Lauer and 
Rozing, 2010).
In CZE, the whole system is filled with a background electrolyte (BGE), whose main 
purposes are to transport the electrical current when a voltage is applied over the system, to 
provide the electrical field strength and to facilitate the separation o f the analytes. Another 
important purpose o f the BGE is pH regulation in order to keep the migration velocity o f the 
analytes and the velocity o f EOF constant, In this way, a stable and reproducible migration 
behavior o f the sample components can be obtained (Lauer and Rozing, 2010).
30
Si Si Si Si Si
O ' O* O* O’ 0*
8 3 8 8 8 h
Anode Cathode
n  e o f --------------- - n
8 8 8 8 8: Mobile layer Fixed layer
O* O ' O- O ’ O '
Si Si Si Si Si
Figure 1. 6. Ionised silica capillary walls illustrating EOF direction.
The concentration o f the BGE plays an important role in separation resolution in 
electrophoresis. If  a constant voltage is applied over the capillary, the electric current will 
increase at higher BGE concentrations and this can cause extra peak broadening due to a 
strong increase in Joule heat. Provided that the generated Joule heat is not too high to affect 
peak efficiency, a higher buffer concentration can produce better peak shapes at high analytic 
concentrations leading to improved peak reproducibility. Ideal separation in CZE is usually 
obtained by using a voltage as high as possible in order to obtain the best separation in the 
shortest time with the best efficiency. However, high voltage leads to difficult heat 
dissipation during the electrophoretic separation due to Joule heat, which is known to affect 
the EOF, diffusion o f analytes, and therefore the efficiency and reproducibility o f  the 
separation, for this reason it is important to control this phenomenon (Xuan et a l., 2006),
In CE, proteins can adsorb to the capillary wall causing alterations o f the EOF and band 
broadening. With the use o f non-coated fused-silica capillaries this can lead to a very poor 
migration time and low plate number. In order to minimise such effects, the separation o f 
protein mixtures is run at extreme pH values, by which either the dissociation o f the silanol 
groups o f the capillary wall is minimised (at acid pH) or the dissociation o f free amino groups 
o f the proteinous solutes is decreased (at high pH values as in the method used, pH 9,18) 
(Lauer and Rozing, 2010).
1.5.2 Principles of high performance liquid chromatography (HPLC)
The goal and purpose o f liquid chromatography is to physically resolve the individual 
components o f a sample from each other so that they may be quantified or identified, A high
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performance liquid chromatography instrument has a number o f components, These include a 
solvent reservoir, a pump, a sample injection system, a column and a detection system, The 
mobile phase (solvent) is a liquid used to carry the sample through the column (where 
separation occurs) and on to the detector (where data is generated), Compounds in trace 
concentrations as low as parts per trillion (ppt) may easily be identified, HPLC has been 
applied to food, nutraceuticals, cosmetics, pharmaceuticals, environmental matrices, forensic 
samples and industrial chemicals,
The choice o f the mobile phase is dependent on the type o f chromatography to be used and 
because o f this the mobile phase can be used as a tool in the optimisation process, A high 
pressure pump is used to push the mobile phase (and sample) through the system, The pump 
is capable of pushing a fixed volume of mobile phase in a fixed time. When the sample is 
introduced into the system, it is carried by the mobile phase onto the column. It is here that 
separation occurs, Columns are typically steel tubes with a variety o f length, diameters and 
packing materials, Again, the choice of stationary phase is based on the type o f compounds to 
be separated. Detection systems are located after the column. When the separated compounds 
leave the column, they pass through the detector where individual signals are recorded for 
each compound, Analytes may be detected by various means such as refractive index, 
electrochemical or ultraviolet-absorbance. The amount of analyte leaving the column will 
determine the intensity of the signal produced in the detector. In reversed phase (RP) 
chromatography, hydrophobic interactions are the primary retention mechanism, The analyte 
is attracted to the hydrophobic surface o f the particle in the stationary phase. Polar 
interactions and primary hydrogen bonding are an important secondary retention mechanism. 
The level o f hydrophobic and polar interaction forces between solute and stationary phase 
will determine the overall solute retention time (Kellner et al., 1998),
Preparative HPLC is used for the isolation and purification o f a product with the sample 
being collected by a fraction collector after identification at required absorption maximum 
wavelength. The amount of compound required to isolate or purify differs dramatically as fig 
quantities are required for isolation o f enzymes while quantities from one to a few mg are 
required for identification and structure elucidation of unknown compounds, Larger amounts, 
in gram quantity, are necessary for standards, reference compounds and compounds for 
toxicological and pharmacological testing (Huber and Majors, 2007),
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1.5.3 Principles of mass spectrometry (MS)
Mass spectrometry is based on the generation o f gaseous ions from analyte molecules, the 
subsequent separation o f these ions according to their mass-to-charge (m/z) ratio, and the 
detection o f these ions. The resulting mass spectrum is a plot o f the relative abundance of the 
ions produced as a function o f the m/z ratio. MS actually measures the relative molecular 
mass Mr o f a compound in atomic units or Daltons (Da) (Kellner et al., 1998).
MS instruments consist o f five parts; sample introduction, analyte ionisation, mass analysis, 
ion detection, and data handling. MS is a combined separation and detection technique and is 
widely applied especially in four major fields; analysis of organic compounds, analysis o f 
inorganic compounds, analysis of surfaces and organic mass spectrometry. MS is the most 
sensitive o f the spectrometric techniques for molecular analysis compared to other techniques 
such as Nuclear Magnetic Resonance (NMR) and infrared spectrometry (Kellner et a l ,  
1998). In Matrix-assisted laser desorption/ionisation (MALDI) analysis the sample is mixed 
with an appropriate matrix-solution, e.g., containing sinapinic acid and deposited onto a 
stainless- steel target, Upon drying, crystallisation occurs and the crystals are bombarded with 
photons, the frequency o f which corresponds to the absorption maximum o f the matrix 
molecules, sample ions are generated which can be mass analysed by a time-of-flight (TOF) 
mass spectrometer. This technique is especially useful for the analysis o f bio-macromolecules 
as compounds with molecular masses up to 300kDa can be detected, A TOF instrument 
consists o f a pulsed ion source, an accelerating grid, a field-free flight tube and a detector 
(Kellner et al., 1998),
1.6 Structural properties involved in ACE-I and PEP inhibitory activities of 
peptides
It has been demonstrated that di- or tri-peptides, especially those with C-terminal proline or 
hydroxyproline residues, are generally resistant to degradation by digestive enzymes 
(Matsufuji et al., 1994, Vermeirssen et al., 2004). In addition, short peptides consisting of 
two or three amino acids are absorbed more rapidly than free amino acids (Gardner, 1988; 
Webb, 1990). The ACE-I inhibitory tripeptides IPP and VPP, for example, were detected in 
the aorta o f Spontaneously Hypertensive Rats (SHR), following oral administration of 
fermented milk (Masuda et al., 1996). Larger peptides (10-51 amino acids) present in the 
diet can also be absorbed intact through the intestine and produce biological effects, although 
the potency o f the peptides decreases as the chain length increases (Roberts et al., 1999).
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However as binding to ACE appears to be strongly influenced by the C-terminal sequence of 
the peptides, it has been suggested that proline, lysine or arginine are the preferred amino 
acids at the C-terminal residue and thus contribute to ACE-I-inhibitory potency (Meisel,
1997), Furthermore, studies in SHR revealed that di-peptides with a C-tenninal tyrosine 
residue produced a slow but prolonged decrease in systolic blood pressure compared to di­
peptides with phenylalanine at the C-terminal, In contrast, di-peptides with a C-terminal 
phenylalanine caused a more rapid reduction in systolic blood pressure and a shorter duration 
o f action (Suetsuna, 1998), Figure 1.7. details information concerning the structural 
conformation o f peptides that may have ACE-I-inhibitory activities.
It has been established that ACE-I inhibitors exhibit antihypertensive activity in vivo 
following administration to Spontaneously Hypertensive Rats (SHR) (Itou and Akahane, 
2004) and hypertensive human patients (Mizuno et al., 2005, Takano, 1998). Some peptides 
are susceptible to degradation or modification in the gut, the vascular system and the liver. 
Several ACE-I-inhibitory peptides with weak in vitro activity produce a strong 
antihypertensive effect in vivo while others lose their activity. An example o f this is the 
peptide Leu-Lys-Pro-Asn-Met, derived from a thermolysin digest o f dried bonito, with an in 
vitro activity o f (IC50= 2,4 fimol/L), but after hydrolysis in vivo, its inhibitory activity was 8 
times higher at (IC50 = 0.32 p.mol/L) (Fujita & Yoshikawa, 1999). In vivo activation or loss 
o f activity is perhaps due to further endogenous enzymatic cleavage (Meisel et al., 2006). 
Interestingly, in vivo comparative studies with Captopril® have shown that ACE-I- inhibitory 
peptides exhibit higher in vivo activity than would be expected from their in vitro activity. 
Fujita and Yoshikawa (1999) found that bioactive peptides have higher tissue affinities and 
are subject to a slower elimination from the body than Captopril®.
The ability o f prolyl residues to protect peptides has led to the evolution o f proline specific 
peptidases such as PEP. Proline has a cyclic structure, which prevents free rotation around 
the cp-bond and, in a peptide sequence Proline does not have a main chain NH proton that 
could form intramolecular hydrogen bonds. Therefore, Proline is unique amongst the 20 
natural a-amino acids. Furthermore it does not participate in hydrogen bonding and can 
prevent hydrogen bonding o f neighbouring residues. Prolyl residues protect biologically 
active peptides from non-specific degradation. The majority o f published PEP inhibitors are 
substrate-like inhibitors that are based on the TV- a c y 1 -L -p r 01 y I-pyrroIidine structure and their 
binding mode to PEP is known. Most PEP inhibitors have a pyrrolidine or a substituted
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pyrrolidine ring at the P 1 site and if  the ring size o f pyrrolidine is decreased or increased by 
one methylene group the inhibitory activity decreases. In addition, pyrrolidine can be 
replaced by other five membered rings including isoxazolidine, thiazolidine, pyrrole, 2,3- 
dihydropyrrole and 2,5-dihydropyrrole but ring opening abolishes PEP inhibitory activity. 
The inhibitory activities o f atypical plant derived PEP inhibitors are unknown to date.
1.7 Bioactive peptides as functional foods
Functional Foods are regulated by Regulation (EC) No. 1924/2006, o f the European 
Parliament and o f the Council, December 20, 2006: nutrition and health claims made on 
foods. This legislation regulates nutritional and or health claims proposed for new products, 
including their presentation, labelling and promotion. Japan was the first country to adopt a 
legal system in relation to allowable health claims on functional foods through the 
introduction of the FOSHU (Foods for Specific Health Use) licensing system in 1991. 
Advertising approval is granted by the Japanese M inistry o f Health to companies’ who can 
prove that a health claim connected to a product has been scientifically evidenced. Between 
2005- 2007, 537 FOSHU products with an estimated value o f US$ 6.3 billion have been 
approved (Hartmann & Meisel, 2007).
During the production o f functional foods containing bioactive peptides, methods must be 
developed to enhance their bioavailability. Functional or novel foods are created by 
fortifying or adding enriched fractions o f the bioactive peptide to the product. Bioactive 
peptides may be produced from precursor protein substrates by a number o f methods such as 
using specific Generally Recognised as Safe (GRAS) proteolytic bacterial enzymes (Hayes et 
a l,  2007; Wang et a l ,  2008b), or enzymatic hydrolysis with digestive enzymes such as 
trypsin and pepsin, (Byun & Kim, 2001; Miguel et a l ,  2009). Other methods include 
endogenous microbial activity o f fermented foods such as cheese and yogurt (Je et a l., 2005). 
Also genetically modified proteins, such as the soybean proglycin A laB lb , can be designed 
to carry multiple copies o f  bioactive sequences (Prak et a l,  2006).
Bioactive peptides may be latent (or encrypted) within the primary or parent proteins and in 
order to exert a physiological response on the various systems in the body proteolysis is 
required for their release and activation (Gobbetti et a l ,  2004), Some of these peptides may
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also act as bio-carriers by sequestering calcium and other minerals and thereby may enhance 
their bioavailability (Silva & Malcata, 2005), Bioactive peptides usually contain between 
two to thirty amino acid residues per molecule (Erdmann et al., 2008),
Digestion o f proteins starts in the stomach by the action o f pepsin at acidic pH 2-3, In the 
more alkaline conditions o f the small intestine, the polypeptides are further cleaved by the 
pancreatic proteases trypsin, a-chymotrypsin, elastase and carboxypeptidase A and B. This 
then results in a mixture o f oligopeptides and free amino acids, o f which the free amino acids 
are absorbed into the enterocytes across the brush border membrane via distinct amino acid 
transport systems. The oligopeptides undergo further hydrolysis by the action o f a number o f 
brush border peptidases, resulting in a mixture largely consisting o f free amino acids and di- 
and tri-peptides (Venneissen et al., 2004), Following digestion, bioactive peptides can either 
be absorbed through the intestine to enter the blood circulation intact and exert systemic 
effects, or produce local effects in the gastrointestinal tract. Depending on the sequence o f 
amino acids, these peptides can exhibit diverse activities, including opioid agonist and 
antagonist activities, mineral-binding, immunodulatory, antioxidative, antiamnesiac, 
antithrombotic and antihypertensive activities (Hartmann & Meisel, 2007; Kitts & Weiler,
2003). Some peptides are multifunctional and can exert more than one o f the effects 
mentioned (Meisel, 2004). The IC50 value (the inhibitor concentration leading to 50% 
inhibition) is used to estimate the effectiveness o f different inhibitory peptides,
1.7.1 Survival of bioactive peptide inhibitors in vivo
Due to the unknown and often incomplete bioavailability of ACE-I or PEP inhibitory 
peptides following oral administration, there is not necessarily an in vivo effect after the 
identification o f an ACE-I/PEP-inhibitory peptide in vitro so it is necessary to perform in- 
vivo animal studies using animal models. In order to determine ACE-I-inhibition in vivo 
Spontaneously Hypertensive Rats (SHRs) are often used. In vivo studies are subsequently 
followed by human dietary intervention studies following the identification o f positive hits 
with in vivo animal trials. An in vitro study using Dictyostelium discoideum  or cellular slime 
mould is used to study the involvement o f PEP in mental health disorders such as biopolar 
disorder. D. discoideum  has the advantage o f  a haploid genome, which enables genes to be 
knocked out easily. Using this organism PEP was found to function as a modulator of 
inositol phosphate signalling a system proposed to be the target o f drugs used to treat bipolar 
disorder (Williams, 2004).
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Figure 1.7. Structure activity correlation between C-terminal tri-peptide sequences of ACE-I- 
inhibitory peptides and the ACE enzyme. A: Binding to ACE is strongly influenced by the 
hydrophobicity of the 3 C-terminal amino acid residues. Aromatic or branched side chain residues 
are preferred. Aliphatic, basic and aromatic residues are preferred in the penultimate positions and 
aromatic, proline and aliphatic residues are preferred in the ultimate position. The positive charge of 
Arginine (R) also contributes to the ACE-I-inhibitory potency of several peptides. A C-terminal 
lysine (K) with a positive charge on the e-amino group also contributes to ACE-I-inhibition. B: 
Trends in hydrophobicity of the L-amino acids. Phenylalanine (F) is the most hydrophobic of the L- 
amino acids and is preferred as one of the C-terminal amino acid residues. The branched aliphatic 
amino acid residues are preferred at the N-terminal end of the ACE-I-inhibitory peptide with the 
exception of Arginine (R). Underlined sequences have previously been identified as ACE-I-inhibitors. 
(Source: Hayes et al., 2007)
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In order to produce antihypertensive or anti-amnesiac effects in vivo, the peptides must be 
absorbed intact through the intestine and reach the target organ/ system in an active form. In 
this regard, specific structural properties play an important role.
1.8 Aims and objectives
Studies on PEP and ACE-I inhibitory peptides derived from fish waste by-products such as 
waste muscle, fins, head and scales are limited with the notable exception o f  enzyme isolation 
from fish viscera. This project will address waste remediation by examining the potential for 
the production o f high-value products other than enzymes from the waste stream, rather than 
regarding the waste as a disposal problem or for the manufacture o f  low economic value 
fertilizers and animal feedstuffs. This project will establish if fish waste from mackerel and 
whelk species is an optimal source for the generation o f ACE-I and PEP inhibitory peptides 
through controlled hydrolysis. Moreover, it will establish what subsequent downstream 
processing methods are necessary for the production o f a high-value peptide product with 
enhanced health benefits and increased economic value.
This project will examine the steps involved in the preparation o f fish waste hydrolysates 
using proteolytic enzymes, the development and implementation o f bioassays to monitor 
ACE-I and PEP inhibitory activities and the concentration o f  the active peptide fractions 
using membrane filtration techniques.
Specific objectives o f this thesis are:
• Can commercially available proteolytic enzymes generate ACE-I and PEP inhibitory 
peptides through the hydrolysis o f fish waste from mackerel and whelk species?
• Which hydrolytic enzymes are more suitable in the generation o f the ACE-I and PEP 
inhibitory peptides?
• What specific fish waste source (waste muscle, head, skin and tail) is likely to 
generate these bioactive peptides?
• Development and implementation o f suitable bioassays to pre-screen marine 
hydrolysate samples for ACE-I and PEP inhibitory activity
• Develop and validate a CE-ACE for the analysis of ACE-I inhibitiory peptides from 
marine hydrolysates,
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• Ascertain if active ACE-I inhibitory hydrolysates can be fractionated using MWCO 
filtration
• Foster a collaborative industrial link with the Errigal Food Company Ltd., Carrick, 
Co. Donegal,
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2. Materials and Methods
2.1 General materials and methods
2.1.1 Chemicals and reagents
Angiotensin-converting enzyme (ACE-I) assay reagents o f purified ACE-I enzyme (EC 
3.4,15.1), crude ACE-I enzyme extract from acetone dehydrated rabbit lung, Captopril®, 
hippuric acid (HA), hippuryl-L-histidyl- L-leucine (HHL), 2,4,6 trinitrobenzene sulfonic 
acid (TNBS), trifluoroacetic acid (TFA), HEPES and sodium tungstate were purchased from 
Sigma Aldrich Ireland Ltd,, Ireland, The substrate hippuryl-glycyl-glycine (Hip-Gly-Gly) 
was supplied by Bachem Holding AG, Bubendorf, Switzerland, Ammonium hydroxide 
(NH4OH), hydrochloric acid (HC1 37%), sodium chloride (NaCl) and sodium hydroxide 
(NaOH) were purchased from Lennox Laboratories (Dublin, Ireland), Potassium di-hydrogen 
phosphate (KH2PO4) was purchased from BDH Laboratory Supplies (Poole, England). De­
ionised water was used throughout and was obtained using a Millipore Direct-Q system 
(ASTM Type 1 18.2 MQ), All other reagents were o f analytical grade.
Purified ACE-I was supplied as a 0.5 mg lyophilised powder containing 5.5 U o f enzyme/ mg 
and was reconstituted in 1.375 mL sterile deionised H2O to give final enzyme concentration 
o f 2 mU/|4.L, Aliquots (25 fj.1) o f purified ACE were stored at -20°C for up to 3 months and 
thawed on ice prior to use. Stock solutions o f purified ACE-I enzyme were further diluted 
tenfold in sterile de-ionised water (225 uL) to yield a final working concentration o f 5 mU/25 
[i L per enzyme reaction. Stock and working solutions o f  crude ACE-I extract from rabbit 
lung dehydrated by acetone were prepared as previously described (Serra et al. 2005). The 
stock solution was prepared by dissolving 2 g o f the powder in 10 mL o f phosphate buffer 
(50 mM, pH 8.3). The solution was soaked overnight under refrigeration (2-6°C) then 
centrifuged for 60 minutes at 13,500 rprn and 4°C. The supernatant was collected and the 
stock solution could be stored for up to 3 months under refrigeration (2-6°C). The working 
solution (1 g/10 mL) was prepared freshly before each assay by diluting the stock solution in 
phosphate buffer (pH 8.3).
Two concentrations o f Captopril® were prepared. For the colorimetric ACE-I assay: a 
Captopril® stock solution o f 1.0 mg/ mL was prepared by dissolving 0.025g in 25 mL o f de­
ionised water. This stock was then diluted to a test concentration o f 0.008 mg/ mL using de­
ionised water as the diluent. For the CE- ACE assay: a Captopril® stock solution (0.1 mg/10 
mL) was prepared by dissolving O.OOlg in 10 mL o f 100 mM sodium borate buffer at (pH
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8.3), This stock was then diluted to the test concentration o f 0.002 mg/ m L using de-ionised 
water as the diluent. The hippuryl-L-histidyl-L-leucine (HHL) substrate solution (1 mM) was 
prepared fresh for each purified ACE-I enzyme assay by dissolving 0.0025 g in 5,0 mL of 
100 mM sodium borate buffer (pH 8.3). The solution was kept on ice until required. The 
substrate solution o f Hip-Gly-Gly (100 mM) was prepared by dissolving 100 mg in 2 mL o f 1 
mM ammonium hydroxide solution. After complete dissolution, the volume was increased to
3.4 mL with de-ionised water and stored on ice until required.
Ammonium hydroxide solution (1 mM) was prepared by adding 5.5 mL ammonium 
hydroxide to 94.5 mL de-ionised water. Sodium tungstate solution was freshly prepared in a 
final concentration o f 1 g/10 mL in de-ionised water. A TNBS solution (6 mM) was prepared 
by dissolving 175 |aL o f TNBS (5%) in 5 mL de-ionised water. Aliquots o f 300 |iL were 
stored at -20°C and used within 3 months. TFA solution (0.1%) was prepared by dissolving 
100 (j L in 10 mL de-ionised water in a 10 mL volumetric flask.
2.1.2 Buffer preparation
The HEPES assay buffer (50 mM), pH 8.3 was prepared by dissolving 1.3015 g HEPES salt 
and 1.7532 g o f  sodium chloride in de-ionised water. The pH was adjusted to 8.3 using a few 
drops o f I M HC1 and volume adjusted to 100 mL, the solution was then vacuum filtered 
through a 0.2 [im polyethersulfone (PES) filter (Pall Life Sciences, Cork, Ireland).
Phosphate buffer (100 mM), pH 8.3 was prepared by dissolving 340.2 mg o f potassium di­
hydrogen phosphate in 20 mL of de-ionised water; pH was adjusted to pH 8.3 using a 10% 
NaOH solution and volume adjusted to 25 mL. This solution was then used to produce a 50 
mM phosphate buffer, pH 8.3 by taking 12.5 mL o f the buffer and adding 12.5 mL de-ionised 
water. Both buffers were vacuum filtered through a 0.2 (im PES filter.
Capillary electrophoresis running buffer (background electrolyte (BGE)) o f 20 mM boric acid 
borate buffer at pH 9.18 was prepared as follows; 0.247 g boric acid was dissolved in 
approximately 160 mL de-ionised water, when fully dissolved 1.526 g o f sodium borate was 
added, solution was stirred until fully dissolved, the pH was then adjusted using a number of 
drops o f 10% NaOH to pH 9.18. Solution was transferred to a volumetric flask and the final 
volume adjusted to 200 mL with de-ionised water and then vacuum filtered through a 0,2 jj.m 
PES,
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The 100 mM sodium borate buffer at pH 8,3 containing 300 mM NaCl was prepared as 
follows: 7.6284 g sodium borate was dissolved in approximately 160 mL de-ionised water, 
when fully dissolved 3.506 g o f sodium chloride was added, solution was stirred until fully 
dissolved, the pH was then adjusted using a number o f drops o f 1 M HC1 to pH 8.3. Solution 
was transferred to a volumetric flask and the final volume adjusted to 200 mL with de-ionised 
water, the solution was then filtered through a 0.2 pm PES filter.
2.1.3 Bradford protein assay
The Bio-Rad protein assay (Alpha Technologies Ltd., Wicklow, Ireland) based on the method 
of Bradford (1976) was used for the detennination o f the concentration o f solubilised protein 
in samples, The assay involves the addition o f an acidic dye to a protein solution, and 
subsequent colorimetric measurement o f the coloured product formed. The absorbance 
maximum for an acidic solution o f coomassie brilliant blue G-250 dye shifts from 465 nm to 
595 nm when protein binding occurs and a differential colour change is observed in response 
to various concentrations of protein. Comparison to a standard curve provides a relative 
measurement of protein concentration in test samples. This method was employed to 
determine the protein content o f both purified ACE enzyme, rabbit lung and hydrolysate 
samples.
A stock solution o f 0.2 mg/ mL o f bovine serum albumin (BSA) (Sigma Aldrich Ireland Ltd., 
Ireland) was freshly prepared and kept on ice, A dilution series o f 2.0, 4.0, 6.0, 8.0, 10.0,
15.0 and 20,0 fig/mL was prepared from the stock solution using de-ionised water as the 
diluent. Each standard and test sample solution (160 pL) was pipetted into separate 
microtitre plate wells and a reference blank solution o f 160 pi de-ionised water was also 
included. Protein solutions were assayed in triplicate. When required test samples were 
diluted using de-ionised water to ensure that their absorbance would fall within the linear 
working range o f the standard curve. Bio Rad dye reagent concentrate (40 pi) was then 
added to each well using a multi-channel pipette. Samples and reagent were mixed 
thoroughly and incubated at room temperature for 10 minutes. Absorbance values measured 
at 595 nm using a microtitre plate reader (Spectrostar Omega, BMG Labtech with Omega 
software version 1.2) were recorded for each standard and test sample. The protein 
concentration o f test samples was determined using the equation o f  a line obtained from the 
standard calibration plot.
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2.2 Enzyme hydrolytic studies
Table 2.1 lists the samples and sample sources used in this study. The main focus o f this 
thesis was to examine whether fisheries processing byproducts are utilizable sources o f ACE- 
I and PEP inhibitory peptides. The following sections outline the steps involved in the 
preparation of fish waste hydrolysates using enzymes, development o f bioassays to monitor 
ACE-I and PEP inhibitory activities, application o f capillary electrophoresis for ACE activity 
and the concentration and purification o f individual peptides using developed 
chromatographic techniques.
2.2.1 Sample pre-treatments
Mackerel and whelk samples from the Cape grounds in Co. Donegal were kindly provided by 
Errigal Fish Company Ltd., in Carrick, Co. Donegal. Mackerel were provided as whole fresh 
fish samples while whelk samples were shell discards from pre-cooked (140°C) processed 
samples and contained some attached cooked meat. Both mackerel and whelk marine samples 
were stored frozen at -20°C,
Whole mackerel samples were de-frosted overnight at 4°C prior to enzymatic hydrolytic 
studies. Mackerel tissues consisted o f white meat, brown meat from the lower dorsal side or 
mackerel head, tail meat and skin portions. Initial studies were performed on mackerel white 
meat samples and the other mackerel tissue sources were examined after optimal enzyme 
hydrolysis conditions were established.
Mackerel white meat tissue samples (approximately 10-20 g portions) were harvested from 
either side o f the backbone and brown meat tissues were harvested from the lower dorsal side 
using a scalpel and cut into 0.5 cm pieces, 100-300 mL o f de-ionised water was added and 
the sample was stomached (Lab blender 400, VWR, Dublin, Ireland) for 40 seconds then 
autoclaved at 105°C for 10 minutes to heat inactivate endogenous enzymes. Mackerel head, 
tail and skin portions were pre-treated in a similar manner but homogenisation o f the tissue 
was performed using an Ultra Turrax homogeniser (IKA, T50 basic Ultra Turrax, VWR, 
Dublin, Ireland). Homogenised and heat inactivated samples were then transferred to a sterile 
500 mL Infors reaction vessel(s) (Infors UK, Reigate, Surrey, England) under aseptic 
conditions using a Class II biological safety cabinet (Microflow, AGB Scientific Ltd.). 
Enzymatic hydrolysis o f tissue samples were performed as described below.
43
T ah ir 2 .1 . Lisi o f samples and sample sources used in lliis study.
S am ples P urpose Source
Marine samples
Mackerel
Whelk
Isolation o f ACE and PEP inhibitors 
Isolation of ACE and PEP inhibitors
Errigal Fish Company Lid*, Co. Donegal 
Errigal Fish Company Ltd., Co Donegal
Hydrolytic enzymes
Ecostone* A200 
Corolase* LAP 
Corolase* N 
Corolase" PP 
Thermolysin 
Pepsin
ACE enzymes
Crude ACIH enzyme 
(rabbit lung extract)
C nrbohydralc hyd lolysi s 
Proicin hydrolysis 
Protein hydrolysis 
Protein hydrolysis 
Protein hydrolysis 
Protein hydrolysis
Colorimetric ACT us,srty
* o  ■$*
A *
AB Enzymes GmbH, Darrmstadl, Germany 
AB Enzymes GmbH, Darrmsiadt, Germany 
AB Enzymes GmbH, Darrmsiadt, Germany 
AB Enzymes GmbH, Damnstadt, Germany 
Sigma Aldrich Ireland Ltd 
Fischer Scientific Ireland l.td
Sigma Aldrich Ireland Ltd
Purified ACE enzyme 
(EC 3.4 15.1)
Capillary electrophorc^is ACE assay Sigma Aldrich Ireland Ltd
ACE substrates
Hippuryl-glycyl-glycme
(Hip-Gly-Gly)
Colorimetric ACE assay Duchem Holding AG, Switzerland
H i ppury! - H i  1st idy l-L- leue me 
(Hip-His-Lcu)
Capillary electrophoresis ACE assay Sigma Aldrich Ireland Ltd
PEP enzyme source
Bovine calf serum PEP foioassuy Queens University Belfast
Prolyl synthetic substrate 
Z*g1ycy l-prolyi - AM C PEP biottssay Queens University Belfast
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Whelk shell samples were retrieved from the -20°C freezer and placed into 500 mL 
beaker, covered and left overnight to thaw. The shell was then ground using a mortar 
and pestle into small pieces (< 1 cm). The shell pieces were rinsed in tap water, 
drained and finally rinsed in de-ionised water to provide a crude cleaning o f samples. 
Fifty grams (wet weight) of washed, crushed shell was placed in a 500 mL beaker 
with 200 mL o f de-ionised water. The mixture was heated to 50°C for 20 minutes on a 
hotplate with stirring and was subsequently transferred to the Infors reaction vessel 
and autoclaved at 121°C for 15 minutes to sterilise and heat-inactivate endogenous 
enzymes. Enzymatic hydrolysis o f whelk shell was performed as described below.
2.2.2 Hydrolytic enzymes and hydrolytic reactions
All enzyme hydrolysis conditions were selected based on the manufacturer 
specification data sheets and the final hydrolytic conditions are provided in Table 2.2. 
Ecostone®A200 (EcoT) is an alpha-amylase preparation produced from a non- 
pathogenic strain of Bacillus species and hydrolyses polysaccharides within an 
optimum pH range is 6-8, Corolase® N (CorN) is a proteolytic enzyme product which 
contains exclusively endo-proteinase activities. It perfonns best at neutral pH and is 
obtained from Bacillus subtilis cultures, Corolase® PP (CorP) is another proteolytic 
enzyme product which contains both endo-proteinase activities and various amino- 
and carboxy-peptidases. It performs best at neutral and slightly alkaline pH 7-9 and is 
obtained from pig pancreas glands. Corolase® LAP (CorL) is a proteinase product 
which contains exclusively exo-peptidase activity. It performs best at slightly acid 
and alkaline pH 6-9 and is obtained from Aspergillus sojae cultures. All of the above 
enzymes were kindly supplied by AB Enzymes (AB Enzymes GmbH, Darmstadt, 
Germany). Pepsin (Pep) is obtained from porcine gastric mucosa and perfonns best at 
acid pH 2-4, and was purchased from Fischer Scientific Ltd. Ireland. Thermolysin 
(TherM) is a thermostable (thermophilic) extracellular metallo-endopeptidase 
containing four calcium ions. Cofactors are zinc and calcium. It hydrolyses protein 
bonds on the N-terminal side o f hydrophobic amino acid residues. The pH optimum is
8.0 and it was obtained from Bacillus thermoproteolyticus which was purchased from 
Sigma Aldrich Ireland Ltd.
An Infors Multifors HT Fermenter controlled by the Infors AG, XDDC system control
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software (Infors UK, Reigate, Surrey, England) was used for all enzyme hydrolysis 
reactions. All glassware, equipment and de-ionised water used in this section were 
sterilised at 121 °C for 15 minutes and Infors fermentation reaction vessels (500 mL 
capacity) were sterilised at 121°C for 30 minutes prior to use.
Table 2.2. Hydrolytic enzymes and optimal hydrolytic conditions selected.
Enzyme Code
Hydrolytic conditions1
% Enz, conc.2 pH Temp Agitation Time
Ecostone®A200 EcoT 5,0% 7,5 60°C 400 rpm 0.3 hours
Corolase® N CorN 4,0% 7.0 55°C 250 rpm 1.0 hours
Corolase® PP CorP 0,5% 8.5 45°C 250 ipm 24.0 hours
Corolase® LAP CorL 0,6% 9.0 60°C 250 rpm 20.0 hours
Pepsin Pep 0.1 - 1.2% 2.5 35°C 250 rpm 2.5 hours
Thermolysin TherM 0,25 - 0.35% 8.0 55°C 250 rpm 18.0 hours
1: Reaction conditions were selected based on manufacturer specifications, 2: Final
percentage enzyme assay concentrations were determined based on the initial weight of tissue 
samples (g/g of sample). All hydrolytic reactions were de-activated by treatment of 80°C for 
15 minutes prior to storage at -20°C or -80°C.
Infors Multifors HT Fennenter system was switched on and reactions parameters 
selected based on optimal hydrolytic conditions (Table 2.2). Reaction vessels with 
marine samples were allowed to equilibrate to selected hydrolytic conditions o f pH, 
temperature and agitation. When all parameters had reached the set conditions for the 
respective hydrolytic enzyme the required amount o f the enzyme was dissolved in 2,0 
mL sterile de-ionised water and injected into the reaction vessel via the sample port. 
Each hydrolytic reaction was run for the specified time period (Table 2.2) and 
reactions were terminated by heat de-activation. For heat de-activation, reaction 
vessels were removed to the Class II biological safety cabinet and hydrolysates was 
decanted into sterile labelled 50 mL plastic falcon tubes. The tubes were placed in a 
water bath at 80°C for 15 minutes to heat de-activate the enzyme reaction. The tubes 
were removed, left to cool and finally stored at -20°C and -80°C.
In the case o f a double hydrolytic enzyme reaction (e.g. Pep and TherM or Pep and 
CorL) the hydrolytic enzyme with the lower pH and temperature parameters (i.e. Pep)
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was ran first for the set conditions and the conditions were then raised to the 
requirements o f the second hydrolytic enzyme (i,e, TherM or CorL), Reactions were 
terminated by heat de-activation as described above,
2.3 Colorimetric ACE-I inhibition bioassay
Preliminary screening o f hydrolysates for ACE-I inhibition was performed using a 
modified ACE-I enzyme assay employed by Serra et al. 2005, The method is based 
on the cleavage o f the substrate hippuryl-glycyl-glycine (HGG) by ACE-I and 
subsequent reaction with trinitrobenzenesulfonic acid (TNBS) to form 2, 4, 6- 
trinitrophenyl-glycyl-glycine, whose absorbance was determined at 415 nm in a 
microtitre plate reader.
Marine hydrolysates were retrieved from -20°C storage and thawed at 4°C overnight. 
ACE-I enzyme reactions were established as follows: 20 (iL o f an crude ACE-I 
enzyme extract from dehydrated rabbit lung (1 g/10 mL) was added to a 1.5 mL 
eppendorf tube containing 20 |iL of mackerel or whelk extract solution, or 30 fil, of 
50 mM phosphate buffer, pH 8.3 (negative control) or 10 (iL o f Captopril® solution 
(0.008 mg/ mL) (positive control). Samples were centrifuged for 30 seconds at 1000 
rpm and pre-incubated for 5 minutes at 37°C, The enzymatic reaction was started by 
the addition o f 80 |iL o f the HEPES assay buffer and 25 uL o f the substrate solution 
Hip-Gly-Gly, After centrifugation at 1000 rpm for 30 seconds to mix contents, the 
samples were incubated for 35 minutes at 37°C. The reaction was stopped by the 
addition o f 100 |iL of sodium tungstate solution (100 g/L) and 100 |iL  o f sulphuric 
acid (0.33 mM) and contents mixed following the addition of 1000 \iL  o f de-ionised 
water. The sample was centrifuged at 1000 rpm for 30 seconds and a 75 |o,L aliquot of 
the supernatant was placed in a microtitre plate (Costar 96-well flat-bottomed plate). 
To assay for Gly-GIy product formation 100 (JL o f phosphate buffer (100 mM, pH
8.3) and 5 |iL o f TNBS (6 mM) solution were added. Microtitre plates were 
incubated in the dark at room temperature for 30 minutes and absorbance (415 nm) 
readings were determined using a microtitre plate reader (Spectrostar Omega, BMG 
Labtech with Omega software Version 1.2). A blank solution was also prepared 
using 70 jiL of 50 mM phosphate buffer with addition of all components except the 
rabbit lung. Assays were performed in triplicate.
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Calculation o f ACE-I inhibition, on percentile basis, was performed using the 
following equation:
Inhibition(%) = 100 -  ( z’A iV
V ^ E  ~  A b  j
jcIOO)
where As is the measured absorbance at 4 15nm in the presence o f  an inhibitor, AB is 
the absorbance o f the blank solution and Ae is the absorbance o f the rabbit lung 
without inhibitor.
2.4 Capillary electrophoresis ACE-I inhibition assay
The enzymatic reaction was based on the liberation o f Hippuric acid (HA) from 
hippuryl-L-histidyl-L-leucine (HHL) substrate catalysed by purified ACE-I enzyme 
(EC 3.4.15.1). ACE-I inhibitory activity was determined by a CE modification of the 
Cushman and Cheung (1971) method. This method was employed in order to verify 
the possible ACE-I inhibitors found using the ACE-I colorimetric assay and also to 
accurately quantify the degree o f inhibition present in the samples.
For direct CE analysis, the total reaction volume was 100 pL, including 25 pL of 
linM  HHL, 25 pL o f 5.0 mU ACE-I and 25 pL o f Captopril (0.002 mg/mL) (positive 
control), 100 mM buffer (negative control) or mackerel/whelk marine hydrolysates 
(test samples). Reactions were prepared in 100 mM sodium borate buffer (pH 8.3) 
containing 300 mM NaCl. All reactions were allowed to incubate at 37°C for 30 
minutes. The enzymatic reactions were terminated by the addition o f 25 pL o f 0.1% 
TFA, All hydrolysate samples were analysed in triplicate. The 100 jiL reaction 
solution was then applied to the CE system for separation and quantification o f HA. 
The amount of HA liberated from HHL per minute in the absence o f ACE-I inhibitor 
was defined as 100% ACE activity. The IC50 value was defined as the amount of 
inhibitor required to inhibit 50% o f the baseline uninhibited ACE activity. The CE 
run buffer (BGE) consisted o f 20 mM boric acid- borate buffer, pH 9.18. The 
percentage ACE-I inhibition was calculated using the following formula:
( Test Sample HA peak area \
% ACE-I Inhibition = 1 0 0 - (  -----------------------------1--------- ---------------------------  xlOO j
H A peak area for ACE enzyme without inhibitor
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All CE analysis were performed using a Beckman Coulter P/ACE ™ MDQ Capillary 
Electrophoresis System equipped with a PD A detector and controlled by means o f the 
CE System software 32 Karat, version 5.0 (Beckman Coulter Ltd., High Wycombe, 
UK), The uncoated fused-silica capillary with an internal diameter o f 75 pm and total 
length of 43 cm, 32 cm from inlet to detector (Composite Metal Services Ltd., 
Shipley, UK) was maintained at 25 °C. To activate a new capillary it was rinsed with 
methanol at 0.5 pounds per square inch (psi) for 10 minutes, followed by 1 N NaOH 
at 0.5 psi for 5 minutes, de-ionised water at 0.5 psi for 10 minutes and finally with the 
BGE at 0.5 psi for 20 minutes, to ensure a clean capillary surface. Daily, before the 
first sample injection, the capillary was flushed with BGE buffer for 3 minutes at 5,0 
psi and after each sample injection and separation the capillary was rinsed with 0.1 N 
NaOH at 5.0 psi for 3 minutes followed by de-ionised water at 5.0 psi for 3 minutes. 
Samples were introduced from the anodic end o f the capillary by hydrodynamic 
injection for 8 seconds at 0.1 psi. The PDA was set at an acquisition range from 190 
to 300 nm at an acquisition rate o f 4 scans per second (4 Hz). The detection 
wavelength was set at 228 nm and the electrophoretic separations were performed at 
20 kV for a ran time o f 5.5 minutes at a capillary temperature o f 25°C. The system 
was run in the normal polarity mode. Data were collected and peak area, height and 
migration time were analysed by the 32 Karat, version 5.0 software. Prior to use, all 
buffers and solutions used in the assay were filtered through a 0.2 pm PES filter.
Weekly the capillary was regenerated by performing a rinse cycle which consisted of 
flushing the capillary with 0.1N NaOH at 1.0 psi for 3 minutes in triplicate, followed 
by de-ionised water at 1.0 psi for 10 minutes, and then with BGE at 1.0 psi for 15 
minutes.
2.4.1 Validation and enzyme kinetic studies for CE method
A set of working HA standards were prepared and used for calculation o f the HA 
concentration. A stock standard solution o f HA was prepared by dissolving HA in 100 
mM sodium-borate buffer (pH 8.3) containing 300 mM NaCl to a concentration o f 2 
mM and stored at 4°C. A series o f 10 mL working standards o f HA were obtained 
from the stock standard solution by dilution with the same buffer over the range 0.01,
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0.025, 0.05, 0.075, 0.10, 0.15 and 0.20 m M . Injections o f standards were performed 
in triplicate in order o f increasing concentration. A calibration curve was obtained by 
plotting the area o f the HA peak on the obtained electropherogram against it’s 
concentration.
The precision o f a method is determined by the extent to which the test results o f 
multiple injections o f standards agree. The precision o f the CE method used was 
expressed in terms o f relative standard deviation (RSD). Linearity is the ability to 
show that the results are directly proportional to the analyte concentrations in samples 
within a given range. This was demonstrated for the CE method employed by 
analysing HA standards in triplicate in the range 0 .0ImM  -  0.20 mM and plotting 
peak area versus HA concentration, a linear trend-line was added to determine the 
degree o f correlation achieved. Values closer to 1.0 show a greater degree of 
correlation.
The limit o f detection (LOD), defined as the lowest concentration o f an analyte that 
the analytical procedure can reliably differentiate from background noise, this was 
evaluated based on a signal-to-noise ratio (S/N) o f 3. The limit o f quantification 
(LOQ) is defined as the level at, or above, in which the measurement precision is 
satisfactory for quantitative analysis. In this case, the LOQ was evaluated based on an 
S/N ratio of 10.
A kinetic study o f ACE was performed at various substrate concentrations ranging 
from 0 to 8.0 mM, all in the presence o f 2.0 mU of the enzyme to verify the above 
described method for ACE assay. One unit (U) o f  ACE activity is defined as the 
amount of enzyme required to catalyse formation o f 1 mM of HA from HHL per 
minute at 37°C under the given conditions. The ACE activity o f each sample applied 
to the CE system could be calculated by quantifying the amount of the HA formed in 
the enzymatic reaction. The velocities o f the ACE-catalysed reactions were calculated 
from the amounts o f HA generated in the enzymatic reaction. The initial velocities at 
various substrate concentrations were plotted as a function o f the HHL concentrations. 
Kinetic data was analysed by linear regression analysis using Lineweaver-Burk plots 
(Whitford, D. 2005).
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2.5 Prolyl endopeptidase activity and PEP inhibition assay 
Prolyl endopeptidase activity from bovine calf serum was determined based on the 
enzyme’s catalytic ability to cleave the prolyl synthetic substrate Z-glycyl-prolyl- 
AMC with the liberation o f the fluorophore 7-amino-4-methylcoumarin (AMC) 
(Goossens et al,, 1992). Prolyl endopeptidase catalytic activity could then be 
calculated based on the amount o f AMC fluorophore product formed, The PEP assay 
and inhibition studies were performed at Queen’s University Belfast (QUB), UK with 
permission from Dr Brian D. Green from the School o f Biological Sciences, and the 
kind assistance o f Danielle Calderwood who supplied all necessary reagents.
Prior to analysis and transport to QUB, all hydrolysate samples were freeze-dried 
using a Christ alpha 1-4 freeze-drier with Vacubrand vacuum pump (SciQuip Ltd., 
Shropshire, UK). Samples were reconstituted in HEPES buffer (50 mM, pH 7,4) to a 
concentration o f  100 mg/ mL (0.025 g in 250 fiL buffer). Bovine calf serum was used 
as the enzyme source (Flavobacterium meningosepticum  is often used as the PEP- 
specific source but as this is pathogenic it was not used). A 50mM Z-Gly-Pro-AMC 
was used as the fluorogenic substrate for the determination o f post-proline cleaving 
enzyme (prolyl endopeptidase). Berberine ^ 3 ,3  |iM) (Sigma Aldrich Ireland Ltd., 
Ireland) was used as the PEP-specific positive inhibitor. HEPES buffer (50 mM) was 
used as a negative control. Greiner black transparent bottomed 96 half well plates 
(Sigma Aldrich Ireland Ltd.) were used in the assay.
PEP activity was assayed as follows; 20|aL o f bovine calf serum was added to each 
microtitre well, 20 |j.L o f each sample or 20 |aL o f berberine or HEPES buffer was 
then added. The assay was initiated by adding 20 p,L o f Z-Gly-Pro-AMC to all wells. 
The plate was then incubated with shaking for 1 hour at 37°C. The enzyme reaction 
was terminated by adding 100 ^L o f acetic acid (3 mM) to each well. All samples 
and controls were run in triplicate, As the test samples were coloured 20 |^L o f each 
sample with no reagents added were run to in order to obtain background colour 
readings, The microtitre plate was then read in a Tecan Safire2 plate reader, model 
IS89 (AQS Manufacturing Ltd., West Sussex, UK) at excitation wavelength 351 mn 
and emission wavelength 430 nm.
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The sample background readings were subtracted from the fluorescence readings and 
the degree o f inhibition (%) was then calculated using the following:
PEP inhibition (%) = contr° l -  (sample - background) » |  qq
control
2,6 Purification of ACE-I inhibitory samples
Hydrolyate samples that strongly inhibited the ACE-I enzyme were selected and 
further purified using a Pall Minimate Tangential flow Filtration system (Fisher 
Scientific Ireland, Dublin, Ireland) equipped with molecular weight cut off (MWCO) 
capsules o f 3kDa and lOkDa, Two samples o f  mackerel were selected, sample M- 
CorN-4 (white muscle meat) and M-CorN-6 (head, tail and skin). Also one sample o f 
whelk W-EcoT-1 which was found to be a potential PEP-inhibitor but negative for 
ACE-I inhibition was selected. Each sample was centrifuged at 2000 rpm for 4 
minutes and the supernatant passed through the lOkDa MWCO capsule and the 
filtrate collected, a sample o f filtrate was analysed for protein content and ACE-I 
inhibitory activity by CE, The remainder o f the filtered samples were stored in acid- 
washed glass bottles at -20°C, For both the mackerel samples, a portion o f the filtrate 
prior to freezing was further filtered through the 3kDa MWCO capsule and the filtrate 
collected, a sample o f filtrate was again analysed for protein content and ACE-I 
inhibitory activity by CE. Between sample filtrations the capsules were thoroughly 
rinsed and cleaned using large volumes o f de-ionised water followed by 0.1 N NaOH.
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3. Results and discussion
3.1 Preparation of ACE-I inhibitory peptides from mackerel and whelk waste
Previous studies have demonstrated that marine sources are suitable for the isolation
of ACE-I inhibitory peptides (Section 1.4, Table 1.1), however no standard protocol is 
recommended, In this study, mackerel and whelk hydrolysates were prepared by 
means o f hydrolysis with commercial enzymes including Ecostone®A200 (EcoT), 
Corolase® N (CorN), Corolase® PP (CorP), Corolase® LAP (CorL), Pepsin (Pep) and 
Thermolysin (TherM). The hydrolysis was necessary in order to release ACE-I 
inhibitory peptides from the inactive forms of intact mackerel and whelk sources, 
Initial enzyme hydrolysis involved the use o f mackerel white meat tissue and crushed 
whelk shell as potential sources o f ACE-I inhibitors, The following six hydrolytic 
reactions were established:
• Whelk shell with EcoT (W -EcoT-1)
• Mackerel white meat with Pep (M -Pep-1)
• Mackerel white meat with CorN (M -CorN-1)
• Mackerel white meat with CorP (M-CorP-1)
• Mackerel white meat with Pep and CorL (M -PepCorL-1)
• Mackerel white meat with Pep and TherM (M-PepTherM-1)
Sample preparation and hydrolytic conditions are described in section 2.2.1 & 2.2,2 
and all hydrolysates were stored at -20°C, Mackerel white meat tissue were digested 
with single proteolytic enzymes or in combination with two proteolytic enzymes to 
examine if double enzyme digests were capable o f generating stronger ACE-I 
inhibitors than single enzyme hydrolysis studies. The alpha-amylase EcoT hydrolytic
enzyme was only used to examine carbohydrate whelk shell hydrolysis and
proteolytic enzymes were not investigated as whelk shell waste contained little or no 
meat tissue.
Hydrolysate samples were retrieved from the -20°C and pre-screened for ACE-I 
inhibitory activity. Initially, hydrolysates were analysed based on the Cushman and 
Chung method (1971) however ACE assays were not reproducible (data not shown). 
A modified alternative colorimetric ACE-I bioassay developed by Serra et al, (2005)
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was employed to screen hydrolysate samples, The method is based on the cleavage of 
the substrate hippuryl-glycyl-glycine (HGG) by ACE-I and subsequent reaction with 
trinitrobenzenesulfonic acid (TNBS) to form 2, 4, 6-trinitrophenyl-glycyl-glycine, 
whose absorbance was determined at 415nm using a microtitre plate reader (Figure
3.1), A crude ACE-I enzyme from rabbit lung dehydrated by acetone was employed 
as the enzyme source and Captopril® was used as a positive ACE-I inhibitor control 
(Section 2.3).
The colorimetric ACE-I bioassay proved successful and reliable at identifying 
potential ACE-I inhibitors from test samples. Using this assay method positive ACE- 
I inhibition for Captopril® ranged from forty to fifty per cent inhibition, Table 3,1 
provides a summary o f the percentage ACE-I inhibition from marine hydrolysate
F igure 3.1. Microtitre plate assay for colorimetric ACE-I bioassay.
samples. Whelk hydrolysate (W-EcoT-1) did not possess ACE-I inhibitory peptides 
since all three replicate samples demonstrated no inhibition o f ACE-1 enzyme activity. 
Conversely, mackerel white meat hydrolysates all demonstrated some level o f ACE-I 
inhibitory activity with the exception o f hydrolysate M-CorP-1, The percentage 
inhibition observed ranged from an average o f twenty six percent to thirty nine 
percent inhibition, The hydrolysate M-CorN-1 exhibited the highest degree of
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potential ACE-I inhibition with a mean value o f thirty nine percent. Mackerel white 
meat hydrolysates with double enzyme digests did not demonstrate increased ACE-I 
inhibition with the percentage inhibition ranging from twenty six to thirty two percent 
for both samples analysed (Table 3.1),
The percentage RSI) calculated for each set o f triplicate samples per analysis ranged 
from eleven to thirty four per cent indicating that the accuracy and precision o f the 
method was highly variable. Possible reasons for this degree o f variation between 
samples and replicates may be due to the enzyme source used and interference from 
other marine proteins in the samples. The ACE-I enzyme employed was a crude 
extract from dehydrated rabbit lung and other components present in the enzyme 
supernatant may have possibly interfered with the enzymatic reaction.
Table 3.1. Percentage ACE-I inhibition for whelk (W) and mackerel (M) 
hydrolysates determined by ACE-I colorimetric bioassay, Sample ID codes are 
described in text,
Sample ID
% ACE-I inhibition1
Rep 1 Rep 2 Rep 3 Mean ± SD % RSD
W-EcoT-1 00.0 00.0 00,0 - -
M-Pep-1 28,0 29.0 41.0 32.67 ±7.23 22.15
M-CorN-1 38,0 32.0 46,0 38.67 ±7.02 18,16
M-CorP-1 0.0 0.0 0.0 - -
M-PepCorL-1 23.0 27.0 29,0 26.33 ±3.06 11,60
M-PepTherM-1 24.0 27.0 44.0 31.67 ± 10.79 34.06
Calculation of % ACE-I inhibition is described in Section 2,3
In order to confirm initial observations, three o f the initial hydrolysis conditions were 
selected and repeated, Frozen tissue samples were recovered from the -20°C and 
hydrolytic conditions were established as described in Section 2.2. In addition, a 
duplicate sample o f mackerel white meat using CorN was established to examine 
reproducibility. The repeat hydrolytic reactions established were:
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• Whelk shell with EcoT (W-EcoT-2)
• Mackerel white meat with CorN (M-CorN-2)
• Mackerel white meat with CorN (M-CorN-3)
• Mackerel white meat with Pep and TherM (M-PepTherM-2)
Results from the repeated hydrolysis for potential ACE-I inhibitory samples by the 
ACE-I colorimetric bioassay confirmed the initial results (Table 3,1 & Table 3,2). As 
observed previously, the whelk hydrolysate W-EcoT-2 did not demonstrate ACE-I 
inhibition activity. Both mackerel white meat hydrolysate samples (M-CorN-2 & M- 
CorN-3) indicated the release o f ACE-I inhibitory peptides with percentage inhibition 
ranging from twenty five and thirty seven per cent (Table 3.2), Although both repeat 
samples were lower than the initial thirty nine per cent observed for M-CorN-1 (Table
3,1) the level o f ACE-I inhibition was considered an acceptable result for 
reproducibility under test conditions employed. Sample M-PepTherM-2 resulted in 
twenty nine per cent potential ACE-I inhibition compared to the initial result o f thirty 
two per cent which also demonstrated good reproducibility.
Table 3.2. Repeat hydrolysis o f whelk (W) and mackerel (M) samples to confirm 
ACE-I inhibition activity. Percentage ACE-I inhibition was determined by ACE 
colorimetric bioassay. Sample ID codes are described in text.
% ACE Inhibition
oampit; id
Rep 1 Rep 2 Rep 3 Mean ± SD % RSD
W-EcoT-2 00.0 00.0 00.0 - -
M-CorN-2 17.0 25.0 34,0 25.33 ±8.50 33.57
M-CorN-3 31.0 33.0 48.0 37.33 ±9.29 24.89
M-PepTherM-2 24.0 26.0 38,0 29.33 ±7.57 25.81
The percentage RSD’s calculated for each set o f triplicate samples per analysis ranged 
from twenty five to thirty four per cent indicating that the accuracy and precision of 
the method was variable as discussed previously. Regardless, the method identified 
potential ACE-I inhibitory peptides from marine hydro lysates and was therefore 
considered suitable for pre-screening samples for ACE-I inhibition. More
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importantly, the conditions established for hydrolysis o f mackerel samples clearly 
indicated the potential o f this tissue source for the isolation o f ACE-I inhibitory 
peptides. All hydrolysate samples were maintained in storage at -20°C prior to further
analysis to confirm and quantify their ACE-I inhibitory potential,
3.2 Confirmation of ACE-I inhibitory activity by capillary electrophoresis 
ACE assay
Although the colorimetric ACE-I bioassay was suitable for pre-screening marine 
hydrolysates to identify potential ACE-I inhibitory peptides the method was not 
accurate in quantifying the percentage ACE-I inhibition in samples, A more robust 
capillary electrophoresis ACE (CE-ACE) assay method was developed to accurately 
quantify the percentage inhibition associated with marine hydrolysates. The 
enzymatic reaction was based on the liberation o f Histidyl-Leucine (HL) and Hippuric 
acid (HA) from Hippuryl-L-Histidyl-L-Leucine (HHL) as a substrate catalysed by 
purified ACE-I enzyme with the resultant HA quantified by CE, Experimental details 
for the CE-ACE assay are described in Section 2.4,
Initial studies involved determining ACE-I assay conditions and investigating the 
linear working range o f the CE-ACE assay. The optimum capillary electrophoretic 
conditions for the ACE reaction mixture were determined based on the methods 
reported by Zhang et al. (2000) and He et al. (2007). In 20 mM boric acid-borax 
buffer, pH 9.18, satisfactory separation o f the reactants and products o f the reaction, 
including HHL, HL and HA was achieved (Figure 3.2). The electropherogram 
illustrates the separation process involved in the CE-ACE assay where the substrate 
HHL control produced a large peak area and height, when the ACE-I enzyme was 
added to the assay reaction this resulted in a reduction in size o f  the HHL substrate 
peak (Table 3.3) as it was catalysed by the ACE-I enzyme to yield HL and HA. The 
HL peak generated from this ACE-I catalysed reaction appears smaller than the HA 
peak as the HL structure does not contain a chromophore (a chemical group capable 
o f selective light absorption) but the HA structure does so it therefore results in larger 
absorbance values for both area and height. The inclusion o f  the positive ACE-I 
inhibitor Captopril® (0.002mg/mL) to catalytic ACE-I enzyme reactions o f HHL 
results in a reduced HA peak area indicating positive inhibition of ACE-I enzyme
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(Table 3.3). The percentage ACE-I inhibition was calculated using the following 
formula:
/ Test Sample HA peak area . . .  x
% ACE-I Inhibition = 100 -  ( ---------------------------- --------- ---------------------------x 100 )
HA peak area for ACE enzyme without inhibitor
The average percentage ACE-I inhibition by Captopril® was calculated at 57.2 ± 4.7% 
for seven individual CE-ACE assays indicating that the assay developed was sensitive 
and reliable for ACE-I inhibition studies.
Time (minutes)
Figure 3.2. Typical CE electropherograms for (A); HHL substrate, (B); purified 
ACE-I enzyme HHL catalytic reaction resulting in two products HL and HA and (C); 
ACE enzyme reaction with positive ACE inhibitor Captopril®.
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Table 3.3, Average CE peak areas and percentage ACE-I inhibition for HHL 
substrate, purified ACE-I enzyme HHL catalytic reaction and ACE-I enzyme assay 
with positive ACE inhibitor Captopril®. Peak areas are a mean o f seven individual 
CE runs for each sample, Typical CE electropherograms are shown in Figure 3.2,
Average peak areas
Sample ------------------------------------------------------------------------  % Inhibition
HHL HA
HHL substrate 19,641 ± 2,908 n/a n/a
ACE-I assay 11,936 ± 2,596 4,483 ± 976 n/a
Captopril® 10,653 ± 2,392 1,917 ± 459 57,2 ± 4.7
n/a = not applicable
There was some variation in migration time for the analytes throughout and between 
analyses. The HA is the most anionic component with an average migration time o f 
approximately 4,7 minutes while less anionic HHL and HL migrated at approximately
3.6 and 3,8 minutes respectively. Captopril® which had an average migration time of 
approximately 5,1 minutes and was used as a positive ACE-I inhibitor control (Figure
3.2). The average migration time for HHL was calculated to be 3.56 minutes and all 
analysis times were between ± five per cent of this time (3.38 -  3,72 minutes). The 
average migration time for HL was calculated to be 3.78 minutes and all analysis 
times were between ± five per cent o f this time (3.66 -  3.90 minutes). The average 
migration time for HA was calculated to be 4.75 minutes, all analysis times were 
between ± five per cent o f this time (4.53 -  4,99 minutes).
This variation may have been caused by temperature fluctuations occurring with the 
run buffer and samples as the sample chamber was not temperature controlled and the 
temperature in the room did vary quite considerably. Temperature variations with 
corresponding changes in run buffer viscosity have been determined to be detrimental 
to obtaining reproducible results, with a change in viscosity o f two to three per cent 
for every 1°C temperature fluctuation (Lauer and Rozing, 2010). Another possible 
reason for the variation in analyte migration time may be due to siphoning from the 
capillary buffer inlet to outlet reservoir if  liquid levels are not kept level. It has been 
shown that a height difference of 2 mm between buffer reservoirs results in a two to 
three per cent shift in migration time for a 50 pm internal diameter (id) capillary
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increasing to 10% for a 100 (j,m id capillary (Lauer and Rozing, 2010), The capillary 
id used for analysis was a 75 (j.m id capillary so this may explain the ± 5% variation 
found.
To determine the linear working range o f the CE-ACE assay a standard calibration 
curve was established for working concentration standards o f  HA (Figure 3,3), A 
strict linear correlation between HA concentration and its peak area was obtained, A 
fresh set o f HA working standards were prepared weekly from the stock standard and 
analysed prior to sample analysis, A regression equation was calculated for each 
analysis with a minimum correlation coefficient o f greater than 0,999 (n =7) obtained 
within the HA concentration range from 0.01 to 0.20 mM. Linearity in the HA 
concentration range indicated no interaction between HA and the electrophoretic 
capillary under the conditions employed. By exploiting the ultraviolet absorbance 
maximum o f HA at 228 nm, the LOD for HA was calculated to be 7.0 |iM and the 
LOQ was calculated to be 24 |iM, During sample analyses, standards at four different 
concentration levels (0,2 mM, 0,1 mM, 0.075 mM and 0.01 mM) were also analysed 
throughout the run to ensure correct calculation o f analyte concentration and also to 
verify the retention time o f analyte(s),
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Figure 3.3, Calibration curve for HA concentration standards from CE 
electropherograms, Correlation co-efficient (R2) o f 0,9997 was achieved and the 
equation o f  the line was; Y = 58402 X + 41.555,
3.2.1 ACE enzyme kinetic analysis by CE-ACE assay
ACE kinetics was studied by changing the amount o f the substrate HHL, in the 
presence o f a fixed amount (2 m il) o f enzyme. The initial velocity for different 
concentrations o f HHL (0-8 mM) was determined by plotting the HA peak area 
obtained (enzyme velocity) against the substrate concentrations to obtain information 
on the substrate saturation o f enzyme. The kinetic data was analysed by Lineweaver- 
Burk plots resulting in a Km  value for purified ACE enzyme o f 1.2 mM. The value o f 
Km  obtained in this study was lower than those reported previously for purified rabbit 
lung ACE, which were 2.60 mM by Cushman et a l  (1971) and 2,30 mM by Das et a l  
(1975) however it was much closer to that o f 1.45 mM as reported by Zhang et a l  
(2000). It is likely that the higher values of obtained by Cushman and Das arose 
from the incomplete separation o f HA from the substrate by solvent extraction using 
ethyl acetate and as it also absorbs at 228 nm. The difference in Km  may also be 
possibly attributed to the different buffer systems used in enzyme assays, with boric 
acid-borate buffer used in this study and by Zhang et al. (2000) while previous 
reports used phosphate assay buffers.
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3.2.2 ACE-I inhibitory activity for marine hydrolysates by CE-ACE assay
Whelk and mackerel white meat hydrolysates were tested for ACE-I inhibitory 
activity using the developed CE-ACE assay. Hydrolysates were retrieved from -20°C 
storage and ACE assay conditions were established as described in Section 2.4. 
Analysis o f ACE activity was determined by CE and percentage ACE-I inhibition 
activity is summarised in Table 3.4. A typical CE electropherogram for one o f the 
mackerel hydrolysates is provided in Figure 3.4. In all cases the level o f ACE-I 
inhibition increased when assayed by the CE-ACE assay, with the exception o f the 
whelk sample hydrolysate. The increase in ACE-I inhibition activity is presumably 
due to the use o f a purified ACE-I enzyme source aligned with the use o f  the more 
sensitive CE analytical method.
Time (minutes)
Figure 3.4. Typical electropherogram o f a sample hydrolysate (M-PepTherM-1). A 
number o f un-identified peaks were observed and are attributed to unknown 
components in the hydrolysate sample.
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Table 3.4. Percentage ACE-I inhibition for whelk (W) and mackerel (M) 
hydrolysates determined by CE-ACE assay. Sample ID codes are described in text.
Sample ID Sample - No.
% ACE-I inhibition
Rep 1 Rep 2 Rep 3 Mean ± SD % RSD
W-EcoT-1 1 00.0 00.0 00,0 - -
2 00.0 00.0 00,0 - >
3 00,0 00,0 00.0 - -
M-Pep-1 1 100.0 100.0 100.0 - -
2 100,0 100.0 100.0 - -
3 100.0 100,0 100.0 - -
M-CorN-1 1 47.0 47.0 43.0 45.67 ±2,31 5.06
2 60.0 69,0 72.0 67,00 ± 6.24 9.32
3 100,0 100.0 100,0 -
M-CorP-1 1 93.0 94,0 92.0 93.00 ± 1.00 1.08
2 93,0 93.0 91,0 92.33 ± 1.15 1.25
3 93,0 91,0 89.0 91.00 ±2.00 2.20
M-PepCorL-1 1 100,0 100,0 100.0 - -
2 100,0 100.0 100,0 - -
3 100,0 100,0 100,0 - -
M-PepTherM-1 1 83.0 86,0 84,0 84,33 ± 1.53 1.81
2 81.0 87.0 82.0 83.33 ±3.21 3.86
3 86,0 80,0 85.0 83.67 ±3,21 3.84
M-CorN-2 1 95,0 91.0 93,0 93,00 ±2,00 2.15
2 94,0 95.0 94.0 94,33 ±0,58 0.61
3 93,0 94.0 94,0 93.67 ±0,58 0.62
M-CorN-3 1 100.0 100.0 100.0 - -
2 100,0 100,0 100,0 - -
3 100,0 100.0 100.0 - -
M-PepTherM-2 1 76,0 76.0 76.0 76,00 ±0,00 0.00
2 72,0 71.0 73,0 72,00 ± 1.00 1.39
3 78.0 80.0 75,0 77.67 ±2.52 3.24
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CE-ACE assay confirmed that the whelk hydrolysate W-EcoT-1 sample did not 
contain ACE-I inhibitory peptides as no inhibition o f ACE-I was observed. However 
sample M-CorP-1 which was negative for potential ACE-I inhibition when tested by 
the colorimetric bioassay showed a high degree o f ACE-I inhibition in the CE based 
assay with samples exhibiting inhibition in the range o f  eighty nine to ninety four per 
cent. All the other samples analysed exhibited ACE-I inhibition by the CE method, 
the percentage o f ACE-I inhibition was higher with this method than the results 
obtained in the colorimetric bioassay in all cases. The % RSI) obtained for all but one 
set o f triplicate samples analysed by the CE method were all below five per cent 
indicating a high degree o f accuracy and precision with this method especially when 
compared to the % RSD’s obtained with the colorimetric bioassay method.
The ACE-I enzyme source used in the colorimetric bioassay, the acetone dehydrated 
rabbit lung was a crude preparation compared to the lyophilized purified ACE-I 
enzyme employed by the CE- ACE assay. In the colorimetric bioassay which was 
developed and verified by Serra et al. (2005) the ACE enzyme was extracted from the 
rabbit lung into the supernatant by spinning in an ultracentrifuge for 40 minutes at 40 
000 x g whereas in this study the rabbit lung was centrifuged at 13,500 rpm (17523 x 
g) for 1 hour as an ultracentrifuge was not available resulting in a less pure or crude 
supernatant enzyme source. This was possibly the reason why triplicate sample results 
showed a degree o f variation. Although there was some variation in the results 
obtained by the colorimetric bioassay, the method was found to be reproducible with 
the repeated hydrolysate analysis which means that it was found to be a valid 
technique for pre-screening o f samples for possible ACE-I inhibitory activity. There 
are a number of advantages in using this technique in that it is less time-consuming 
than the CE assay method and employs only inexpensive reagents, enzyme source and 
a relatively inexpensive microtitre plate reader capable o f analysing 96-well plates 
leading to rapid throughput o f samples.
The three repeat hydrolysate samples of mackerel white tissue meat hydrolysed with 
Corolase® N (M-CorN-1, -2 and -3) all exhibited a high degree of ACE-I inhibition 
with the CE-ACE method with the first sample average being seventy one per cent 
and the subsequent two samples each recording averages o f ninety four and one
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hundred per cent respectively. Sample M-CorN-1, the first Corolase® N hydrolysate 
was the only sample that exhibited any inconsistency between the set o f three 
triplicate samples tested with an ACE-1 inhibitory range o f forty six to one hundred 
per cent. This was the first sample investigated using this set o f hydrolysis conditions 
so was stored for a slightly longer period o f time than the two repeat samples possibly 
leading to degradation o f the sample or an experimental error may have occurred 
during the assay procedure as one o f the three samples resulted in one hundred per 
cent ACE-I inhibition. This may have been a contributing factor to the lower 
percentage ACE-I inhibition found in the CE-ACE assay as this sample in the initial 
pre-screen was found to have the highest potential ACE-I inhibition when analysed by 
the colorimetric bio-assay.
The CE-ACE assay results demonstrated that the hydrolysate sample M-Pep-1 was a 
strong ACE-I inhibitor with one per cent inhibition recorded. This sample was 
hydrolysed with pepsin employing conditions analogous to those in the human 
stomach. The purpose o f this selection o f hydrolysis conditions was to determine if 
consumption o f mackerel white tissue meat would result in natural generation of 
ACE-I inhibitors in the body. The results found from both ACE assays indicate that 
this possibility is indeed feasible and would suggest that the consumption o f mackerel 
white tissue meat may be beneficial to the diet, especially for those who suffer from 
hypertension.
3.3 ACE-I inhibitory peptides from different mackerel tissue sources
Having established that mackerel white meat tissue was a suitable source for the 
isolation o f ACE-I inhibitory peptides other mackerel tissue sources were examined. 
Particular emphasis was placed on discard sources such as head, skin and tail portions. 
Corolase® N was selected as a suitable hydrolytic enzyme since it had previously 
demonstrated its repeatability to generate ACE-I inhibitory peptides from mackerel 
white meat tissue. The following hydrolytic reactions were established and sample 
preparation and hydrolytic conditions are described in section 2.2.1. & 2.2,2:
• Mackerel white meat with CorN (M-CorN-4)
• Mackerel brown meat with CorN (M-CorN-5)
• Mackerel head, skin and tail with CorN (M-CorN-6)
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Hydrolysates were pre-screened for ACE-I inhibition activity using the ACE-I 
colorimetric bioassay (Table 3.5) and assayed by the CE-ACE method to accurately 
determine the percentage o f ACE-1 inhibitors present (Table 3.6).
Table 3.5. Percentage ACE-I inhibition for different mackerel tissue hydrolysates 
determined by ACE-I colorimetric bioassay. Sample ID codes are described in text.
% ACE- Inhibition
Sample ID --------------------------------------------------------------------------------------
Rep 1 Rep 2 Rep 3 Mean ± SD % RSD
M-CorN-4 30,00 36,00 39.00 35.00 ±4,58 13.09
M-CorN-5 24,00 35.00 37.00 32.00 ± 7.00 21.88
M-CorN-6 26.00 23,00 45.00 31.33 ± 11,93 38.08
Table 3,6. Percentage ACE-I inhibition for different mackerel tissue hydrolysates 
determined by CE-ACE assay. Sample ID codes are described in text.
% ACE-Inhibition
Sample ID »ampieNo. Rep 1 Rep 2 Rep 3 Mean ± SD % RSD
M-CorN-4 1 100.00 100.00 100.00 - -
2 100.00 100.00 100.00 - -
3 100.00 100.00 100.00 - -
M-CorN-5 1 100.00 100,00 100.00 - -
2 100.00 100.00 100.00 - -
3 100.00 100.00 100.00 - -
M-CorN-6 1 95.00 97.00 95.00 95,67 ± 1.15 1.21
2 96.00 90,00 93.00 93.00 ±3.00 3.23
3 94.00 94,00 94.00 94.00 ± 0.00 0.00
The hydrolysis o f mackerel white tissue meat with Corolase® N sample M-CorN-4 
resulted in thirty five per cent potential ACE-I inhibition by the ACE colorimetric 
bioassay method. This result is almost identical to that obtained with the previous 
samples indicating excellent reproducibility with the repeated hydrolysis conditions.
66
IThis completed a quadruple set o f identical hydrolysis conditions employed for this 
sample o f mackerel white tissue meat.
Sample M-CorN-5, the brown meat tissue sample resulted in thirty two per cent 
potential ACE-I inhibition by the ACE-I colorimetric bioassay method, Sample M- 
CorN-6, the head, tail and skin sample resulted in thirty one per cent potential ACE-I 
inhibition by the ACE colorimetric bioassay method. All three hydrolysate samples 
were similar for ACE-I inhibition activity which demonstrated a similar degree of 
ACE-I inhibitor generation by the Corolase® N hydrolysis for different mackerel 
tissue sources, The percentage RSD’s obtained for the triplicates o f each sample again 
varied from thirteen to thirty eight per cent and this variation has previously been 
discussed.
As previously observed the CE-ACE assay was more sensitive and accurate at 
quantifying ACE-I inhibitory activity. The percentage RSD ’s for all triplicate 
samples analysed by the CE-ACE method were all less than three point two per cent 
and the majority o f replicate samples had zero per cent RSD indicating a high degree 
o f accuracy and precision with this method (Table 3,6). Hydrolysates M-CorN-4, the 
white meat tissue sample, and M-CorN-5, the brown meat tissue sample, resulted in 
one hundred per cent ACE-I inhibition by the CE ACE assay method. Sample M- 
CorN-6, the head, tail and skin sample resulted in an average o f  ninety four per cent 
ACE-I inhibition by this method, These results indicate that Corolase N is a suitable 
proteolytic enzyme for the release o f potential ACE inhibitory peptides from different 
mackerel tissues sources, hi addition, the fact that discard mackerel portions o f head, 
tail and skin portions could be utilised as a novel tissue sources for the discovery of 
potent ACE-I inhibitory peptides might be economically beneficial to the seafood 
processing sector.
3.4 Purification of ACE-I inhibitory peptides from mackerel hydrolysates
Previous studies have indicated that ACE-I inhibitory peptides are usually between 2- 
30 amino acids (Table 1.1) and that these bioactive peptides can be concentrated by 
molecular weight cut off (MWCO) and/or by ultra-filtration through 3 and lOKDa 
membrane filters. Three samples were chosen for purification based on their ACE-I
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inhibitory peptide activity. Two mackerel samples, M-CorN-4, a white meat tissue 
sample and M-CorN-6, a head, tail and skin sample were selected. Both these samples 
were found to contain potent ACE-I inhibitors and as the samples were taken from 
different parts o f the mackerel there was a possibility they may have contained 
different ACE-I inhibitory peptides. The third sample selected was the whelk sample 
W-EcoT-1 which was included as negative control for ACE-I inhibition, All three 
hydrolysate samples were retrieved from the ~20°C freezer and defrosted before 
filtering through a Pall Minimate lOKDa MWCO capsule filter and samples were 
subsequently filtered through a second Pall Minimate 3KDa MWCO capsule filter as 
described in Section 2,6.
Protein content for each filtered sample was determined by the Bio-Rad protein assay 
based on the method o f Bradford (1976) and was used for determination o f the 
concentration o f solubilised protein in samples, The assay involves the addition o f an 
acidic dye to a protein solution, and subsequent measurement with a microtitre plate 
reader, A differential colour change o f a dye occurs in response to various 
concentrations o f protein, The absorbance maximum for an acidic solution of 
Coomassie Brilliant Blue G-250 dye shifts from 465 nm to 595 nm when binding to 
protein occurs, Comparison to a standard curve provides a relative measurement of 
protein concentration, Each o f the three selected samples was analysed in triplicate to 
determine their total protein content as per the method described in Section 2.1.3, The 
corresponding MWCO filtered samples were also analysed to determine if  the 
filtration process resulted in a reduction in protein content (Table 3.7).
A standard curve was used to determine the concentration o f protein present in the 
samples by substitution o f the sample absorbance into the equation o f the line 
generated (Figure 3.5),
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Figure 3.5. BSA calibration curve for protein determination, Correlation coefficient 
(R2) = 0.9941 (n = 7) was achieved and the equation o f the line was: Y = 0.0389X + 
0.0741.
Table 3.7. Bio-Rad protein assay for lOkDa and 3kDa MW CO filtration samples.
Sample ID
Total protein (jig/ml)
Rep 1 Rep 2 Rep 3 Mean ± SD % RSD
W-EcoT-1 79.20 68.50 82.60 76,77 ±7.36 9.59
W-EcoT-1 lOkDa 0.00 0.00 0.00 - -
M-CorN-4 140.00 177.65 188.00 168.55 ±25.26 14.99
M-CorN-4 lOkDa 39.00 45.00 53.00 45.67 ±7.02 15.38
M-CorN-4 3kDa 4.80 3.40 5.80 4.67 ± 1.21 25.83
M-CorN-6 113.40 125.60 117,48 118.83 ±6.21 5.23
M-CorN-6 lOkDa 10.94 9.55 11.35 10.61 ±0.94 8.89
M-CorN-6 3kDa 5.62 5.57 5.60 5.60 ±0.03 0.45
The total protein content o f  all the three samples tested was reduced considerably by 
the filtering process. As each sample was successively filtered through smaller
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MWCO capsules the amount o f protein present also decreased. In the case o f  the 
whelk shell sample W-EcoT-1 all protein was removed when the sample was filtered 
through the lOkDa MWCO capsule. Conversely, both mackerel hydrolysates retained 
protein fractions when filtered through the 3kDa MWCO capsule (Table 3.7).
After filtration, each sample was analysed in triplicate using the CE-ACE assay 
method to quantify ACE-I inhibitory activity and to determine if  the filtered fractions 
still retained ACE-I inhibition activity or if  it was removed by the filtering process 
(Table 3.8). Stacked electropherograms o f the three samples showing their filtered 
and unfiltered profiles were compared to confirm that the samples appeared more 
purified after each filtration step illustrated by the reduction in the number o f peaks in 
their profile (Figures 3.6, 3.7 and 3.8).
As previously observed W-EcoT-1 hydrolysate was inactive for ACE-I inhibition and 
the lOkDa filtered samples which contained no protein fraction were also inactive 
(Table 3,8, Figure 3.8). Filtered mackerel hydrolysates still retained positive ACE-I 
inhibition activity suggesting that ACE-I inhibitory peptides were less than 1 OkDa in 
size (Table 3,8, Figures 3,6 & 3.7). Hydrolysate sample M-CorN-4 prior to filtration 
possessed an average o f one hundred per cent ACE-I inhibition (Table 3.6). After 
sample filtration through the lOkDa MWCO capsule the average ACE-I inhibition 
percentage remained at one hundred per cent, After filtration through the 3kDa 
capsule it was found to be ninety one per cent a reduction o f nine per cent with 
percentage RSD’s o f less than one point two per cent for each set o f triplicates. It was 
concluded that the active ACE-I inhibitory component in this filtered hydrolysate was 
smaller or equal in size to 3kDa which would account for only the slight reduction in 
activity by the second filtration step.
Hydrolysate sample M-CorN-6 prior to filtration possessed an average o f ninety four 
per cent ACE-I inhibition (Table 3.6). After sample filtration through the lOkDa 
MWCO capsule the average ACE-1 inhibition percentage was determined to be eighty 
two per cent a reduction o f twelve per cent with percentage RSD’s o f less than two 
per cent for each set o f triplicates.
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Table 3.8. Percentage ACE-I inhibition for lOkDa and 3kDa MWCO fdtration of 
selected marine hydrolysates. ACE inhibition activity was determined by CE-ACE 
assay. Sample ID codes are described in text,
% ACE-Inhibition
Sample ID Sample No. Rep 1 Rep 2 Rep 3 Mean ± SD % RSD
W-EcoT-1 lOkDa 1 0.0 0.0 0.0 - -
2 0,0 0,0 0,0 - -
3 0,0 0.0 0.0 - -
M-CorN-4 lOkDa 1 100,0 100.0 100,0 - -
2 100,0 100.0 100.0 - -
3 100.0 100.0 100,0 - -
M-CorN-4 3kDa 1 92.0 93,0 92.0 92,33 ±0.58 0.63
2 92.0 91.0 92.0 91.67 ±  0,58 0.63
3 87.0 89,0 88,0 88.00 ± 1.00 1.14
M-CorN-6 lOkDa 1 82.0 82,0 82.0 82.00 ±0.00 0.00
2 75.0 73,0 73.0 73.67 ± 1.15 1,57
3 91.0 92.0 92.0 91.67 ±0.58 0,63
M-CorN-6 3kDa 1 0.0 0.0 0.0 - -
2 65.0 50,0 64.0 59.67 ±8.39 14.06
3 i 0 0 0,0 0.0 - -
After filtration through the 3kDa capsule it was found to be zero per cent (in two of 
the three samples), It was concluded that the active ACE-I inhibitory component was 
larger than 3kDa but smaller or equal in size to 1 OkDa which would explain why there 
was no inhibition with the smaller size fraction, It appeared that a possible 
experimental error occurred in sample two as only this one sample o f the three 
analysed exhibited an average o f sixty per cent inhibition, The percentage RSD 
obtained was also very high for the triplicates o f this sample at fourteen per cent. It 
was most likely that the full aliquot o f  ACE enzyme, 25 pL was not added to this 
sample due to a pipetting error resulting in less HA production which appeared as 
inhibition. The decision to analyse three samples in triplicate each time for this assay 
method due to the small aliquots being measured was verified by highlighting this 
type o f error.
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The filtration process identified possible different ACE-I inhibitory peptides 
associated with mackerel hydrolysates. Considering that both mackerel hydrolysates 
were digested under the same conditions and using the same Corolase* N proteolytic 
enzym e the difference in potential ACE-I inhibitory peptides might be assumed due to 
differences from various mackerel tissue sources i.e. while meat tissues (M-CorN-4) 
as opposed to head, skin and tail portions (M-CorN-6). Alternatively, the ACE 
inhibitory peptide associated with each mackerel hydrolysate may be similar and 
incomplete o f partial hydrolysis by Corolase® N may not have released the active 
3kDa fraction from mackerel head, tail and skin portions (M-CorN-6). Further studies 
would have to clarify i f  the amino acid sequence is similar for both lOkDa and 3kDa 
fractions.
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Figure 3.6. Stacked electropherogram for unfiltered, lOKDa and 3KDa filtered M- 
CorN-4 hydrolysate. ACE inhibition activity was determined by CE-ACE assay as 
described in Section 2.4
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Figure 3.7. Stacked electropherogram for unfiltered, lOKDa and 3KDa filtered M- 
CorN-6 hydrolysate. ACE inhibition activity was determined by CE-ACE assay as 
described in Section 2.4
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Figure 3.8, Slacked electropherogram for unfiltered and lOKDa filtered W-EcoT-1 
hydrolysate. ACE inhibition activity was determined by CE-ACE assay as described 
in Section 2.4
3.5 Preliminary screening o f marine hydrolysates for PEP inhibitory activity
A wide variety o f PEP inhibitors have been described in scientific literature (Jarho, 
2007) with several PEP inhibitors chemically synthesised (Morain et al., 2002), In 
addition, PEP inhibitory peptides have been found in a variety o f  food sources as 
outlined in Table 1.2. As part o f this study it was decided to investigate if  marine 
hydrolysates generated for ACE inhibitory peptide studies were active for PEP 
inhibitory peptides. The PEP assay chosen for this preliminary screening o f marine 
hydrolysates was prolyl endopeptidase activity from bovine calf serum. Prolyl 
endopeptidase activity from bovine calf serum was determined based on the enzym e’s 
catalytic ability to cleave the prolyl synthetic substrate Z-glycyl-prolyl-AMC with the 
liberation o f the fluorophore 7-amino-4-methylcoumarin (AMC) (Goossens et al. 
1992), Prolyl endopeptidase catalytic activity was then calculated based on the 
amount o f AMC fluorophore product formed, All the hydrolysed samples were pre­
screened for possible PEP inhibitory activity using this assay method and assays were 
performed at Queens University Belfast as described in Section 2.5.
The positive PEP- inhibitor berberine inhibited the bovine calf serum enzyme source 
by an average of forty six per cent, Unexpectedly, all marine hydrolysates analysed 
were positive for inhibition o f bovine calf serum with inhibitory activity ranging from 
thirty four to eighty per cent inhibition depending on the hydrolysate examined (Table 
3.9). All samples were run in triplicate and there was excellent consistency between 
the triplicates as all % RSD’s recorded were all below eight per cent, demonstrating a 
high degree o f accuracy and precision was obtained with the analysis method, The 
average PEP inhibitory activity for the whelk hydro lysate W-EcoT-1 was thirty five 
per cent which was less than the berberine positive control. The average PEP 
inhibitory activity for all other hydrolysates were greater than the berberine positive 
control suggesting that these samples were potential novel sources o f PEP inhibitory 
peptides. There was only slight difference between mackerel tissue sources and 
proteolytic enzyme employed in determining PEP inhibitory activity, however M- 
CorN-6 yielded higher PEP inhibitory activity (>76%) for all three replicate samples. 
This observation might suggest that head, tail and skin mackerel portions may be a 
suitable target for future PEP inhibitory studies.
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These preliminary observations only demonstrate the potential for identifying PEP 
inhibitory peptides from marine waste sources. Future work could explore the use o f 
a more specific PEP enzyme source from Flavobacterium meningosepticum  (Yanai et 
al. 2003) however on this occasion time did not permit.
Table 3.9. Percentage PEP inhibiton for whelk (W) and mackerel (M) hydrolysates 
determined by PEP fluorogenic assay. Sample ID codes are described in text.
Sample ID
% PEP-Inhibition
Rep 1 Rep 2 Rep 3 Mean ± SD % RSD
W-EcoT-1 34.28 34.85 36,85 35.33 ± 1.35 3.82
M-Pep-1 69.60 63.90 61.11 64,87 ±4,33 6.67
M-CorN-1 47.77 53.36 55.88 52,34 ±4.15 7.94
M-CorP-1 77.01 72.49 68.43 72,64 ± 4,29 5,91
M-PepCorL-1 71.27 71.25 75.24 72,72 ±2,54 3.49
M-PepTherM-1 63.62 64.46 68.60 65.46 ±2,78 4,24
M-CorN-2 69.18 69.96 68.37 69.17 ±0.79 1.14
M-CorN-3 64,71 62.05 61.46 62.74 ± 1.73 2,76
M-PepTherM-2 69.07 69.81 69,83 69.57 ±0.43 0.62
M-CorN-4 63,42 65.03 61.67 63.37 ± 1.68 2.65
M-CorN-5 67.46 66.97 69.63 68.02 ± 1.42 2.08
M-CorN-6 77,06 76.51 80,00 77.86 ± 1.88 2,41
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4 Conclusions and future work
Like many natural resource-based processing industries, the seafood processing sector gives 
rise to a significant volume o f organic waste, an estimated 45% of which arises in the northwest 
region of Ireland (Pfeiffer 2003). Environmental issues, economic concerns and legal 
restrictions regarding the disposal of processing wastes have led to increased research in the 
discovery o f alternative value-added products, such as bioactive peptides from these waste 
streams, Maximising profitability from the available supply o f raw material is recognised as 
a priority for the marine processing sector (Marine Institute’s Sea Change Strategy 2007- 
2013). This necessitates increasing the proportion o f the catch destined for human 
consumption and secondly extracting high value products such as pharmaceuticals and 
functional food ingredients from the waste stream, Bioactive compounds o f both scientific 
interest and commercial value may be available for extraction directly from marine 
processing waste or alternatively may be formed from components present in the waste by 
microbial fermentation and/or enzyme hydrolysis steps before extraction is undertaken. 
Identification o f bioactives of natural origin is a growing field and the use o f fish processing 
by-products as substrates to generate high-value bioactive products is a new approach with 
potential for the functional foods sector. The main focus o f this thesis was to examine 
whether mackerel and whelk fisheries processing by-products and mackerel meat tissues are 
suitable sources for the isolation o f angiotensin-I-converting enzyme (ACE-I) and prolyl 
endopeptidase (PEP) inhibitory peptides.
The initial problem in the isolation of bioactive peptides from natural sources is the 
establishment o f  proteolytic hydrolysis conditions. In this study, mackerel and whelk 
hydrolysates were prepared by examining different commercial enzymes including 
Ecostone®A200, Corolase® N, Corolase® PP, Corolase® LAP, Pepsin and Thermolysin, All 
enzyme hydrolysis conditions selected were based on the manufacturer specifications and the 
final hydrolytic conditions are provided in Table 2,2, Hydrolytic reactions were controlled 
by use of an Infors Multifors HT Fermenter which allowed for standardisation of reaction 
conditions and offered the ability to repeat hydrolytic conditions when necessary, The 
approach o f using different hydrolytic enzymes was to identify a suitable enzyme source for 
the releases o f bioactive peptides. Preliminary screening o f marine hydrolysates using either 
single or double enzyme digests indicated that this approach was suitable for the release of 
potential ACE-I and PEP inhibitory peptides (Section 3,1 & 3,5), Future studies could
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explore altering the hydrolytic parameters such as pH, temperature and incubation period o f a 
single selected hydrolytic enzyme in order to optimise enzyme activity and release of 
bioactive peptides,
A fundamental aspect in the characterisation o f bioactive peptides is the development o f 
suitable and reliable assays for the detection o f the target peptide. Issues of cost, speed, 
specificity, sensitivity and reliability are major concerns in the selection o f suitable assays. In 
addition, bioassays have the ability to pre-screen samples in order to determine if  candidates 
are selected for further studies. Since ACE-I and PEP inhibitory peptides were the bioactive 
peptides o f interest, suitable bioassays for these peptides were examined for pre-screening o f 
marine hydrolysates.
Prolyl endopeptidase activity and inhibition studies were determined by the method o f 
Goossens et al. (1992) and this bioassay method suggested that all marine hydrolysate 
samples contained potential PEP inhibitory peptides (Table 3.9), This bioassay was simple 
and rapid to use and had the only special requirement a Tecan Safire2 microtitre plate reader. 
The other advantage of this bioassay was the ability o f the assay to simultaneously screen 
multiple samples using the microtitre plate reader. Although, all marine hydrolysate samples 
were positive for potential PEP inhibitory peptides the assay should be repeated to confirm 
initial observations and future work should explore the use o f a more specific PEP enzyme 
source from Flavobacterium memngosepticum  (Yanai et a l, 2003). These preliminary 
observations only demonstrate the potential for identifying PEP inhibitory peptides from 
marine waste sources.
Cushman & Cheung (1971) is the standard method for determining ACE-I inhibitory activity 
and the assay relies on the release o f HA from HHL substrate using a purified ACE enzyme 
source. The method requires several steps and the HA can be contaminated with ethyl acetate 
which also absorbs strongly at 228 nm unless fully evaporated using nitrogen evaporation 
(Roy et a l ,  2000). Although the method was attempted in this laboratory using Captopril® 
as a positive ACE-I inhibitory control the method proved unreliable under test conditions 
(data not shown). An alternative and validated colorimetric ACE-I bioassay by Serra et al. 
(2005) was employed to screen marine hydrolysate samples (Section 2.3 & 3.1). This ACE-I 
colorimetric assay was suitable for pre-screening samples for ACE-I inhibitory activity since 
the positive Captopril® ACE inhibitory control yielded forty to fifty per cent inhibition and as
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reported in this study the mean percentage ACE-I inhibition for positive marine hydrolysates 
ranged from twenty five to thirty nine per cent inhibition (Table 3,1; Table 3,2 & Table 3.5), 
These percentage ACE-I inhibition values correspond well with the reported values o f 8% to 
57% for plant extracts by Serra et al. (2005) using the same method. The particular 
advantages of the colorimetric ACE bioassay were the use of inexpensive reagents and crude 
ACE enzyme extract, the short assay time and the ability to simultaneously screen multiple 
samples using the BMG Labtech microtitre plate reader capable o f  analysing 96-well plates 
leading to rapid throughput o f samples, The disadvantages included the poor sensitivity o f the 
assay (see below), the variability in accuracy and precision o f the assay (Section 3,1) and the 
requirement for a microtitre plate reader.
Although the colorimetric ACE-I bioassay was suitable for pre-screening marine hydrolysates 
to identify potential ACE-I inhibitory peptides the method was not accurate in quantifying the 
percentage ACE-I inhibition in samples, A more robust capillary electrophoresis ACE (CE- 
ACE) assay method was developed to accurately quantify the percentage inhibition 
associated with marine hydrolysates, ACE activity was determined by a CE modification o f 
the Cushman and Cheung (1971) method and optimum capillary electrophoretic conditions 
were determined based on the methods reported by Zhang et al. (2000) and He et al. (2007) 
(Section 2,4). The CE method developed in this study was extremely sensitive (Section
3.2,2), had a rapid analysis time (< 5minutes) and was accurate to less than five per cent RSD 
for all positive ACE-I inhibitory marine hydrolysates (Table 3,4 & 3,6). In addition the 
method could be automated with the inclusion an auto-sampler to the Beckman Coulter 
P/ACE ™ MDQ Capillary Electrophoresis system, Moreover the method requires much less 
sample, substrate and other reagents and has high reproducibility (Zhang et al. 2000), This 
approach should prove to be valuable in developing diagnostic methods of ACE activity 
assay and screening for ACE inhibitory peptides.
As the majority o f ACE-I inhibitors discovered to date are peptidic in origin, the main focus
for determination of possible ACE-I inhibitors was reserved for the mackerel tissues. It was
• i ®found that commercially available proteolytic enzymes, in particular Corolase N were 
capable o f generating novel ACE-I inhibitory peptides through the controlled hydrolysis o f 
fish waste and meat tissue from mackerel. Mackerel body parts such as white muscle tissue, 
head, skin and tail were found to generate active ACE-I inhibitory bioactive peptides,
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Positive ACE-I inhibitory activity as determined by CE-ACE bioassay ranged from seventy 
one to one hundred per cent depending on the mackerel tissue source and hydrolytic enzyme 
employed (Table 3.6).
Based on the ACE-I inhibitory studies o f mackerel tissue two ACE-I inhibitory mackerel 
tissue samples were selected for further concentration and purification. Sample M-CorN-6, 
the head, tail and skin sample prior to concentration possessed an average o f ninety four per 
cent ACE-I inhibition. After sample filtration through the lOkDa MWCO capsule the 
average ACE-I inhibition percentage was determined to be eighty two per cent a reduction o f 
twelve per cent. After filtration through the 3kl)a capsule it was found to be zero per cent. It 
was concluded that the active ACE-I inhibitory component was larger than 3kDa but smaller 
or equal in size to lOkDa which would explain why there was no inhibition with the smaller 
size fraction (Table 3.8). Sample M-CorN-4, a mackerel white tissue sample, prior to 
concentration possessed an average o f one hundred per cent ACE-I inhibition. After filtration 
through the lOkDa MWCO capsule the average ACE-I inhibition percentage remained at one 
hundred per cent. After further filtration through the 3kDa capsule it was found to be ninety 
one per cent a reduction o f only nine per cent (Table 3.8). It was concluded that the active 
ACE-1 inhibitory component in this sample was smaller or equal in size to 3kDa which would 
account for only the slight reduction in activity by the second filtration step.
Results indicated that the experimental strategy employed and the utilisation o f marine waste 
from mackerel and whelk species may serve as an approach to identifying bioactive peptides 
capable o f generation o f ACE-I and bovine calf seium PEP inhibitors through controlled 
hydrolysis. The potential for development o f these techniques in search o f bioactive peptides 
for human exploitation from marine processing wastes would bring increased value to what is 
today considered an environmental waste problem. As two mackerel hydrolysates M-CorN-4 
3kDa and M-CorN-6 lOkDa were generated from different mackerel tissue sources (Section 
3.4) there is the possibility that these hydrolysates may possess different ACE-I inhibitory 
peptides and may be o f novel origin. Future work would include further purification and 
characterization o f the concentrated ACE-I inhibitory samples using RP-HPLC followed by 
peptide sequence elucidation using M ALDI-T'OF MS analysis or Edman degradation studies.
This project addressed the issue of waste remediation by examining the potential for the 
production of high-value products other than enzymes from the waste stream, rather than 
regarding the waste as a disposal problem or for the manufacture o f low economic value
80
fertilizers and animal feedstuffs. Advances in bioprocess engineering technologies such as 
more efficient design and development o f manufacturing equipment and processes such as 
bioreactors, together with novel use o f nanotechnology methods such as using chitin, chitosan 
and crab shell waste fermentation products to encapsulate functional food ingredients 
(Srinivosa and Tharanatham, 2007) will mean that fish processing wastes in the future may 
serve as inexpensive raw materials in the generation o f high-value bioactive compounds 
which may have a variety o f applications (Kim and Mendis, 2006), Development of these 
technologies will ensure the exploitation o f potential added-value products from this waste 
stream and will present unique challenges and opportunities for the seafood industry 
worldwide. As ACE-I and PEP inhibitors can be sourced from naturally occurring plants and 
herbal remedies the possibility that hypertension and PEP associated disorders may be 
modulated through dietary intake is a real possibility.
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